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ABSTRACT 
Bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BHV-1) cause 
economically important diseases in cattle that are not completely controlled by current 
vaccines. The T lymphocytes are known to serve an important role in immunity to these 
diseases. Cattle have CD4'* ,^ CDS" ,^ and yS subsets of T lymphocytes that have both 
complementary and redundant roles in disease resistance. Determining the relatively 
unknown contribution of different T lymphocyte subsets in the immune response to BVDV 
and BHV-1 may significantly advance vaccine development and further describe the bovine 
immime system. Expression of the interleukin-2 receptor a chain (CD25) was used to detect 
T lymphocytes reactive to BVDV and BHV-1 in animals vaccinated or experimentally 
challenged with these viruses. Animals vaccinated with a modified live vaccine (MLV) 
containing BVDV genotype 1 (BVDV 1), BVDV genotype 2 (BVDV 2), and BHV-1 
developed CD4"*', CDS" ,^ and yS T lymphocytes reactive to both genotypes of BVDV and 
BHV-1 in vitro. Animals vaccinated with a MLV containing BVDV 1 and BHV-1 
developed CD4'^ , CDS'*", and y5 T lymphocytes reactive to BVDV 1 and BHV-1 and also 
developed CDS"  ^and y5 T lymphocytes reactive to BVDV 2. The vaccinated animals were 
also protected from challenge with virulent BHV-1 at 110 days after vaccination. Young 
calves with high titers of maternally derived antibody to BVDV did not develop a humoral 
immime response to challenge with virulent BVDV 2. Compared to nonexposed calves, the 
calves exposed to BVDV 2 after ingestion of high titer colostrum demonstrated greater 
activation of CD4'^ , CDS"* ,^ and y5 T lymphocytes by in vitro BVDV 1 and BVDV 2, and 
were protected from virulent BVDV 2 challenge after maternal antibody had waned. These 
vi 
results show that BVDV and BHV-1 specific T lymphocytes of the dM"*", CDS"* ,^ and y8 TCR 
phenotype are generated following exposure of cattle to these antigens. Protection from 
BVDV and BHV-1 challenge was demonstrated in cattle with T lymphocytes specific for 
these viruses, although correlation of these two events requires further investigation. Calves 
exposed to BVDV v l^e maternal antibody levels are high can develop protective BVDV 
specific T lymphocyte responses in the absence of a detectable himioral immune response. 
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CHAPTER 1: GENERAL INTRODUCTION 
Dissertation organization 
This dissertation is composed of a general introduction, two literature review chapters, 
three manuscripts, and a general summary. The first literature review chapter summarizes 
the role of T lymphocytes in response to viruses, with special emphasis placed on the role of 
y5 T cells and the T lymphocyte response to bovine viral diarrhea virus. The second 
literature review chapter entitled '^ Influence of immunological maturity and maternally 
derived antibodies on cell mediated immune responses to pathogens in yoimg calves" will be 
submitted for publication as a review article. The manuscript entitled "In vitro detection of 
antigen specific bovine CD4"* ,^ CD8" ,^ and yS T lymphocyte responses following vaccination 
with modified live pestivirus and herpesvirus" will be submitted to Veterinary Immunology 
and Immunopathology for publication. The manuscript entitled "Immime response in cattle 
vaccinated with two genotypes of killed or live bovine viral diarrhea virus" will not be 
submitted for publication due to inconclusive results. The manuscript entitled "Cell 
mediated immunity to bovine viral diarrhea virus in calves protected by maternal antibody" 
will be submitted to Veterinary Microbiology for publication. The references cited in each 
chapter are listed at the end of the respective chapter. The general summary chapter 
discusses the implications of the research presented in this dissertation and suggests 
directions for continued research. 
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Research summary 
The role of T lymphocytes in the immune response to disease in cattle is not well 
described. Cattle have dM"*", CDS'*", and y5 subsets of T lymphocytes that have both 
complementary and redimdant roles in disease resistance. Bovine viral diarrhea virus 
(BVDV) and bovine herpesvirus 1 (BHV-1) cause economically important diseases of cattle 
that are not completely controlled by current vaccines. The T lymphocytes are known to play 
an important role in immunity to BVDV and BHV-1, but the contribution of the different T 
lymphocyte subsets is not well understood. Research that furthers the understanding of T 
lymphocyte responses to these viruses may significantly advance the development of 
protective vaccines. A two color flow cytometric technique to detect activated bovine T 
lymphocytes by CD25 expression was ad^ted in our laboratory from similar procedures 
used in other species'. This technique was standardized and streamlined to accommodate the 
large numbers of animals needed for the research presented in this dissertation. 
In the first trial, activated T Ijonphocytes specific for BVDV genotype 1 (BVDV 1), 
BVDV genotype 2 (BVDV 2), and BHV-1 were detected in animals immimized with these 
viral antigens. Animals vaccinated with a modified live vaccine (MLV) containing BVDV 1, 
BVDV 2, and BHV-1 developed CD4% CDS"*", and y5 T lymphocytes reactive to both 
genotypes of BVDV and BHV-1 antigens in vitro. Animals vaccinated with a MLV 
containing BVDV 1 and BHV-1 developed CD4'*", CDS"* ,^ and y8 T lymphocytes reactive to 
BVDV 1 and BHV-1, and also developed CDS'*" and y6 T lymphocytes reactive to BVDV 2. 
The vaccinated animals were also protected from challenge with virulent BHV-1 at 110 days 
after vaccination. The second trial was conducted to investigate the differences between T 
lymphocyte subsets activated by killed vaccines and those activated by modified live 
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vaccines. The measurements of antigen specific T lymphocytes and protection from BVDV 
challenge in this trial were not interpretable for reasons discussed in chapter 5. 
In the third trial, young calves with high titers of maternally derived antibody to 
BVDV were challenged with virulent BVDV 2 to measure the development of BVDV 
specific T lymphocytes and to assess protection from BVDV challenge after catabolism of 
maternal antibody. Calves that were fed colostrum with a high titer against BVDV did not 
develop a measurable humoral immune response to BVDV. Calves exposed to BVDV 2 
after ingestion of high titer colostrum were protected from clinical disease, demonstrated 
greater activation of CD4"*", CDS"*", and y5 T lymphocytes by in vitro BVDV 1 and BVDV 2, 
and were protected from a later challenge compared to nonexposed calves. This 
demonstrates that calves infected with BVDV while maternal antibody levels are high could 
develop a specific T lymphocyte response to BVDV in the absence of a detectable humoral 
immune response. 
Reference 
1. Quade, M. J. and J. A. Roth. 1999. Antigen-specific in vitro activation of T-lymphocyte 
subsets of cattle inmiunized with a modified live bovine herpesvirus 1 vaccine. Viral 
Immunol. 12:9-21. 
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CHAPTER 2. LITERATURE REVIEW OF CELL MEDL\TED IMMUNITY TO 
VIRUSES BY CATTLE 
Introduction 
The importance of T lymphocytes in the acquired immune response to viral pathogens is 
well established. A majority of literature describing the ilmctional activity of T lymphocytes 
in the bovine immune response is based on whole lymphocyte populations. The specific 
roles of 004" ,^ CD8\ and y6 T lymphocytes in response to economically important diseases 
of cattle are not well defined. The activity of CIM"*" and CDS"*^ T cells in viral immunity in 
cattle described to date indicate functions similar to well described counterparts in humans 
and mice. The activity of y6 T lymphocytes in response to pathogens is not well defined in 
any species. Gamma delta T lymphocyte responses to pathogens will be thoroughly 
examined in this review, as this subset may represent an especially important component of 
the bovine immune repertoire. Bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 
(BHV-1) cause disease of considerable economic importance to the dairy and beef industry. 
T lymphocyte responses play an important role in protection of cattle from these two 
diseases, but the role of different T lymphocyte subsets is not established. Development of 
protective vaccines could be significantly advanced through a broader understanding of the T 
lymphocyte responses to these important diseases. This may be especially true for 
development of B VDV vaccines due to the diversity of the viral genome. 
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Immvine Responses to Viral Invasion 
Introduction 
Two branches of the immune system, innate and acquired immunity, cooperate to 
prevent viral replication, neutralize infectious particles or clear vitally infected cells from the 
host. The innate immune mechanisms are especially important early in viral infection for 
preventing or slowing viral spread, and for providing activation signals to the acquired 
immune responses. Innate responses lack specificity for any particular pathogen and lack 
memory resulting from previoxis exposure. The acquired (specific) immune responses are 
specialized to clear specific viruses and have memory for that virus. 
Innate immunity to viruses 
The most important elements of the innate immune response to viruses are; production 
of interferon, stimulation of macrophages and natural killer cells, activation of the 
complement cascade, and production of antimicrobial peptides. Interferons are secreted 
proteins expressed following viral replication within a cell that confer antiviral effects on 
neighboring cells. Interferons suppress protein synthesis by activating a protein that 
phosphorylates the eIF2 protein, a component of the transcription activation complex. This 
is very effective against viruses that rely on host cell protein machinery to replicate and 
assemble. IFN also activates a host RNA endonuclease that degrades viral RNA. IFNy also 
activates macrophages, which phagocytose virus particles and present antigen to the cells of 
the acquired immune system. Natural killer (NK) cells are also activated by INFy and are 
cytotoxic to cells expressing surface proteins that are indicative of viral infection. In 
addition, IFNy upregulates expression of the major histocompatibility complex molecules I 
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and II, which present antigen to the T lymphocytes. The complement cascade has also been 
shown to be directly activated by some viruses, resulting in opsonization of virions for 
phagocytosis by macrophages or direct damage to virus membranes by the complement 
membrane attack complex. Antimicrobial peptides released from neutrophils or epithelial 
cells in response to infection can disrupt viral membranes and direct the response of innate 
and acquired immune cells to viral invasion. 
Acquired immunity to viruses 
The B and T lymphocytes mediate acquired immimity; their specificity derives from the 
complementarity of the viral peptide sequences with the lymphocyte receptors. The B 
lymphocytes recognize sequences on intact viruses and synthesize mass quantities of 
antibodies that react with those peptide sequences and may neutralize the virus. This 
neutralization occurs by prevention of viral entry into cells, enhancement of phagocytosis by 
macrophages, or by enhancing cytotoxicity from NK cells. The T lymphocytes recognize 
small sequences that are presented on the surface of an infected cell or antigen-presenting 
cell through class I or IIMHC molecules. The helper (ClW  ^T cells recognize peptides 
presented on MHC 11 molecules by antigen presenting cells. Once activated by binding its 
ligand, the helper T cells secrete small protein molecules (cytokines) that signal the 
appropriate immune response. Helper T cells are further subdivided into Thl and Th2 
subsets depending on the cytokine profile produced by the cell. Thl cells primarily secrete 
IFNy and IL-2, which activate macrophages and act as a T cell growth factor respectively. 
Th2 cells secrete mainly IL-4, IL-5, IL-6, and IL-10 that stimulate a predominant antibody 
response to pathogens. The Thl response is generally the most effective response to 
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intracellular pathogen invasion. The cytotoxic (CDS'*) T cells recognize antigen presented by 
MHC I molecules on any virally infected cell. The cytotoxic T cells kill virally infected cells 
via perforin and granzyme molecules, or by delivering a death signal through their Fas 
ligand. T lymphocytes expressing CIM"  ^or CDS"*" accessory molecules usually express the 
ap T cell receptor. Another subset of T cells express the y8 T cell receptor and is especially 
abundant in the blood of rxmiinant animals. The fimction of y8 T cells in protective immunity 
is not well understood nor easily generalized across species. Thus, further discussion of the 
current literature on yd T cells role in immunity is warranted. 
Role of yST cells in cell mediated immunity to viruses 
Compared to humans or mice, the peripheral blood of ruminant animals contains a larger 
percentage of T cells that are of the y5 phenotype. Up to 70% of the T cells in the peripheral 
blood of young calves may be y5 T cells'. This nimiber decreases with age to 5-25% of the 
circulating T cells', and is still a greater proportion of the total circulating T cell population 
than that observed in humans or mice .^ It has been speculated that the large percentage of y§ 
T cells in young ruminants may confer temporary protection to newborns to help compensate 
for the lack of immunoglobulins in the bloodstream at birth .^ Conclusive evidence for the 
role of larger numbers of yd T cells in ruminants compared to other species, however, is not 
available. The large nimiber of y8 T cells in the circulation of ruminants is frequently 
exploited for research purposes to study yS T cell function. Although the Literature 
describing aspects of y6 T cell function is abimdant, the current level of knowledge regarding 
the role of yS T cells is minimal compared to the extensively defined roles of aP T cells. The 
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available literature demonstrates that major differences between the two T cell populations 
are observed in physiological distribution, surface morphology, size, expression of surface 
markers, tra£5cking, antigen recognition, and co-stimulatory pathways required for 
activation. Gamma delta T cells also appear to share many ftmctional roles with ap T cells, 
including the production of cytokines and cytolytic activity against infected or damaged 
cells. 
The y5 T cells from peripheral blood of cattle are significantly smaller than the a|3 T 
cells .^ In addition, the cell surface of bovine y8 T cells is characterized by additional 
microvilli'*, allowing them to express iq) to 5 times more L-selectin .^ This property has 
considerable impact on the trafBcking and cellular interaction properties of yS T cells, as Avill 
be discussed below. In general, yS T cells express the CD3 molecule, but do not express the 
€04"*  ^or CD8"  ^accessory molecules present on aP T cells. Expression of memory markers 
common on other lymphocytes, such as the CD45RO isoform, has not been described for y5 
T cells. An interesting observation made with bovine yS T cells is the ability to express large 
quantities of MHC II molecules, a property generally confined to antigen presenting cells .^ 
Bovine y5 T cells are usually categorized based on the presence or absence of the workshop 
cluster 1 (WCl) antigen and the CD2 molecule. Properties denoting fiirther subdivisions 
have recently been described based on binding patterns to GD3.8, GD3.1, or GDI97 
monoclonal antibodies .^ 
The physiological distribution and trafiBcking patterns of y5 T cells differ from those of 
aP T cells. Although present in differing proportion among species, y5 T cells can be 
isolated from blood, lymph, skin, and gut epitheliimi^ . Gamma delta T cells trafBc through 
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the lymph nodes, spleen, Peyers Patches, and thymus, but unlike ap T cells do not usually 
localize at these lymphoid sites^. Some y8 T cells do localize in the peripheral cortex area of 
bovine lymph nodes, v^ereas ap T cells localize in the paracortex area .^ The paracortex is 
an important location for T cells to interact with antigen presenting cells and become 
activated. As discussed below, the absence of yS T cells in this location provides fiirther 
evidence for altered activation requirements of y8 T cells in comparison to aP T cells. 
The siuface markers on bovine yS T cells vary with location. Gamma delta T cells in the 
blood and afferent lymph express WCl and not CD2 ,^ whereas y5 T cells in the spleen and 
gut epithelium express CD2 and not WC1*. The y6 T cells localized in the bovine spleen 
have recently been shown to have a GD3.8+/GD3.1-/GD197- monoclonal antibody binding 
pattern .^ The functional significance of this discovery is unclear, although y5 T cells that 
bind the GD3.1 antibody preferentially accumulate at sites of inflammation  ^ The molecule 
that the GD3.1 antibody binds may have a role in adhesion or transmigration of this cell 
population at sites of inflammation 
The trafficking pattern of y5 T cells differs from that of other lymphocytes. Gamma 
delta T cells preferentially recirculate through extralymphoid sites such as the skin, gut 
mucosa, and inflamed tissue instead of secondary Ijonphoid sites .^ As previously mentioned, 
y5 T cells have 2-5 times more surface expression of L selectin than other lymphocytes .^ 
This property allows y8 T cells to more effectively initiate rolling adhesion on endothelial 
monolayers, platelets, and immobilized yS T cells compared to other lymphocytes'"". 
Although demonstrated ex vivo, the enhanced ability of y6 T cells to roll on various adhesive 
substrates is likely correlated to an enhanced ability to tra£Bc through tissue m vivo. 
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Interactions with other cells in an immune response could also be significantly enhanced by 
the increased expression of L seletin or other adhesion molecules. 
The preferential localization of yS T cells at epithelial stirfaces and the ability to respond 
to less specific stimuli are frequently interpreted to indicate that yS T cells are a first line of 
defense in protective immunity .^ Antigen recognition by y8 T cells differs significantly from 
that of a(3 T cells. Presentation of antigen to y5 T cells is usually not restricted by MHC 
molecules, unlike ap T cells'^ *'^ . In contrast to the specific peptides required for activation 
of aP T cells, y6 T cells can be activated by a variety of microbial and tumor antigens. 
Specifically, y5 T cells appear to be able to recognize alkenyl or prenyl derivatives of 
phosphates, pyrophospates, or nucleoside triphosphates on the surface of cells .^ It is 
currently not clear whether y5 T cells recognize these phosphoantigens presented on a 
cellular surface in context with a microbial component, or if they recognize a self molecule 
(e.g. heat shock protein) upregulated on the surface due to infection or transformation'^ . 
There is also evidence that y6 T cells can be activated by allogeneic MHC II molecules, 
nonclassical MHC I molecules, heat shock proteins, and a molecular transporter molecule 
specific to macrophages'^ . The abundance of potential antigens in nature makes it difBcult to 
explain how yS T cells recognize antigen, especially given the limited repertoire of y5 TCR 
genes .^ One report, however, indicates that there may be a link between the response of y5 T 
cells to nonclassical MHC I molecules and heat shock proteins. Human yS T cells proliferate 
in response to the nonclassical MHC I molecule MICA, which is under the control of a heat 
shock protein inducible promoter'^ . Greater exploration of antigen presentation to y5 T cells 
will provide a wealth of information regarding the fimction of these cells. Antigen 
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recognition described for human and mouse yS T cells may not apply to bovine cells of this 
phenotype. The bovine y6 TCR has a much more genetically diverse repertoire and may 
have different antigen recognition capabilities compared to other species .^ 
The relative lack of y5 T cells in the lymph node or spleen has been proposed to indicate 
that this T cell subset does not rely on activation signals from professional antigen presenting 
cells (APC) .^ The current literature regarding interactions of y5 T cells with APCs and 
costimulatory signals for y6 T cell activation appear to support this conclusion. Unlike ap T 
cells, y§ T cells from cattle do not proliferate in response to allogeneic dendritic cells'^ . In 
this same study, CD28 transcripts were isolated from aP T cells, but not from y5 T cells. The 
CD28 molecule on T cells interacts with the CD80/86 (B7) molecules on antigen presenting 
cells and is the most important co-stimulatory signal for activation of aP T cells. The lack of 
CD28 costimulation in the previous study may indicate that y5 T cells require antigen and 
costimulatoiy signals to proliferate. Alpha beta T cells can proliferate when exposed to 
concanavalin A in the absence of antigen presenting cells or exogenous IL-2'^ . In the same 
report, purified y5 T cells required either an antigen presenting cell or exogenous IL-2 in 
order to proliferate in response to concanavalin A. In agreement with Howard and 
colleagues'^ , the inability of y5 T cells to proliferate in the current trial also seemed to 
correlate with the lack of CD28 expression". Antibodies to the WCl molecule on bovine y5 
T cells stimulate this population to proliferatebut it has not been determined if the WCl 
molecule serves a role in costimulation. 
The functional activities of yS T cells appear to closely resemble those of aP T cells. 
The important effector functions of aP T cells are the production of cytokine molecules that 
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direct the appropriate immune response and the generation of cytotoxic cells enable of 
killing infected or altered cells. The current literature indicates that y5 T cells share these 
general capabilities. Production of IL-2 from mouse y8 T cells and production of IL-2 and 
IFNy from human y8 T cells has been demonstrated in individuals exposed to bacteria^® '^. 
Gamma delta T cells from mice are also able to produce IL-4 in response to a parasitic 
infection^®. Cattle vaccinated with ovalbumin (OVA) also have y8 T cells that proliferate and 
produce TNFa when exposed to OVA in vitrei^ . In the same study, y6 T cells from cell lines 
cultured in OVA produced TNFa, IL-4, IFNy, and the p35 chain of IL-12 in response to in 
vitro exposure to OVA. It is interesting to note that in the previous study, transcripts for IL-2 
or IL-12 were not detected in the fresh yS T cells or the y6 T cell lines after in vitro exposure 
to OVA. This observation may explain the need for exogenous IL-2 for proliferation of y5 T 
cells in response to concanavalin A discussed previously* .^ In autologous mixed lymphocyte 
reactions, however, y5 T cells and ap T cells from cattle produced similar amounts of IL-2 
and IFNy in response to autologous cells that have been altered by extensive culture .^ The 
population of y5 T cells in this study was not pure and may have reflected effects from a 
small population of aP T cells. 
The division of ap helper T cells into distinct subsets based on cytokine profiles 
(production of IL-4, IL-5, IL-6, and IL-10 denotes Th2 and production of IL-2 and IFNy 
denotes Thl) also appears to be appropriate for yS T cells .^ Alpha beta T cells of the Thl 
type are most effective at activating immune cells that control intracellular invasions such as 
viruses, while Th2 cells augment an antibody response from B cells that is effective at 
controlling extracellular invasions. Limited research indicates that the roles of Thl and Th2 
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cells expressing the yS T cell receptor may be analogoiis to their aP counterparts. Mice 
infected with the extracellular parasite Nippostrongylus brasiliensis have y8 T cells that 
produce IL-4 in In the same study, mice infected with the intracellular bacteria 
Listeria monocytogenes have y6 T cells that produce IFNy in vivo. Ferrick and colleagues 
reported two additional interesting observations in this study^°. The peak of IFNy production 
by y5 T cells from the peritoneal cavity coincided with the greatest amount of macrophage 
recruitment to this tissue. In addition, the production of IL-4 and IFNy by y5 T cells in 
response to both pathogens occurred earlier and in greater quantity compared to production 
by 004"*" T cells. Other evidence suggests that y8 T cells may play a role early in infection or 
inflammation by secreting cytokines that recruit the appropriate cellular immune response. 
Concanavalin A stimulated yS T cells recruit aP T cells on microchamber slides by releasing 
MlPla, MIP P, RANTES, and lymphotactin, but do not specifically recruit macrophages '^*. 
Gamma delta T cells arrive at sites of inflammation or antigen challenge earlier than their aP 
T cell counterparts, but this migration is not antigen specific'^ . 
The ability to produce cytokines that direct immune responses to antigen appears to be a 
property shared by aP T cell and yS T cells. The fimctional role of cytokine production by 
these two subsets, though, may be quite different. Alpha beta T cells produce cytokines in 
response to specific recognition of antigenic components displayed by MHC molecules on 
antigen presenting cells. The ability of y5 T cells to produce cytokines jqspropriate to the 
antigenic challenge may result from recognition of molecules (e.g. heat shock proteins, 
nonclassical MHC molecules) expressed by infected cells. These molecules may be 
upregulated by cells in response to a particular class of pathogen (e.g. virus versus bacteria) 
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and not to a specific pathogen. Recognition and response to nonspecific classes of antigen 
early in infection would support the hypothesis that y6 T cells function as a bridge between 
innate and acquired immunity^ 
Cytolytic activity by y5 T cells has also been described, but the literature is limited and 
conflicting. Human y6 T cells can develop cytolytic activity against allogeneic or autologous 
targets^ .^ Lymphokine activated killing (LAK) of tumor cells by human y5 T cells has also 
been described '^. Bovine yS T cell lines repeatedly stimulated with Babesia bovis are able to 
kill targets in a manner consistant with LAK activity '^. Freshly isolated bovine yS T cells, 
however, were unable to kill K562 cells (LAK target) after culture in LAK media .^ These 
authors proposed that cytotoxic activity by y6 T cells may be an artifact of long term cell 
culture and not a general functional property .^ A very recent report describes cytotoxic 
activity of bovine yS T cells against an envelope protein from bovine leukemia virus (BLV). 
Gamma delta T cells from alymphocytic cattle infected with BLV, but not from BLV 
negative cattle, were able to lyse target cells expressing the envelope protein in vitro^ .^ It 
was interesting to note that ability of the yS T cells to kill their target was restricted by the 
expression of the envelope protein and not by the genetic makeup of the target cell. 
One very important difference between y6 T and ap T cells is the ability to have 
memory to a specific antigen. The aP T cells are characterized by the ability to have 
cognitive memory responses following immunization with an antigen. Initial reports 
indicated that y5 T cells were unable to generate a memory response following antigenic 
challenge^®"^ .^ This is in conflict with the many reports of antigen specific proliferation, 
cytotoxic activity, and cytokine secretion discussed in the current review. 
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Alpha beta and gamma delta cells appear to have functions that are redimdant and 
complementary to each other. Future studies will need to separate the effects of antigen from 
the effects of cross talk between the two cell subsets. In addition, it is important to further 
define the growth factors, antigens, and costimulatory signals reqiiired to activate yS T cells. 
Functionally different subsets of y5 T lymphocytes are apparent both intra- and inter-
specially. Conclusions based on the activity of one subset of y5 T lymphocytes should be 
interpreted carefully and not xised to broadly define the activity of all y6 T lymphocytes. 
Immune responses of cattle to bovine viral diarrhea virus 
Bovine viral diarrhea virus infection of cattle 
Bovine viral diarrhea virus (BVDV) is an economically devastating pestivirus that is 
ubiquitous in the world cattle population. Epidemiological studies indicate that 
approximately 60-85% of cattle have circulating antibody against BVDV^ .^ The financial 
consequences of infection are difBcult to measure since infection is frequently subclinical 
and clinical presentations vary with the strain of the infecting virus. Mucosal disease, acute 
infection, decreased milk production, poor reproductive performance, pneumonia, 
hemorrhagic syndrome, sudden death, abortions, congenital defects, growth retardation, and 
increased susceptibility to other pathogens are all potential outcomes of BVDV infection^^ .^ 
Estimates of the financial losses due to BVDV infection range from $20-57 million dollars 
per million calvings and vary with the virulence of the infection^  ^
Transmission of BVDV between animals can occur through infected saliva, urine, feces, 
oculonasal discharge, semen, placenta, amnionic fluid, uterine secretions, needles, transferred 
embryos, as well as by transplacental movement'^ . Cytopathic (cp) and noncytopathic (ncp) 
biotypes of the virus are present in cattle populations and are differentiated by their effects on 
cell culture^ .^ Both biotypes are capable of causing disease^^^®. Acute infections are usually 
mild and clinical symptoms persist for only a few days '^* .^ Noncytopathic BVDV strains are 
the most commonly isolated biotypes from acutely infected animals in the field^ .^ 
Persistently infected (PI) animals occur when an animal is infected in utero with a ncp 
BVDV during the first trimester of gestation '^Persistently infected cattle are the most 
important source of transmission in a herd due to the large numbers of virus constantly shed 
by these animals^ '^^ . The incidence of PI cattle in herds is generally low (1-2%)^ ,^ but one 
PI animal can infect the majority of a calf herd due to the large amounts of virus shed by 
these animals. Fatal mucosal disease can develop when an animal persistently infected with 
a ncp BVDV strain is subsequently infected with a genetically similar cp BVDV strain '^ 
The virus has also been separated into two separate genotypes (BVDV 1 and BVDV 2) based 
on differences in monoclonal antibody binding patterns and genomic differences in the 5' 
untranslated region of the viral genome^*. Isolates from severe acute disease, especially 
those causing hemorraghic syndrome are usually BVDV Many other isolates of 
BVDV 2 have been identified in infected animals and fetal calf serum that are not necessarily 
associated with severe acute BVDV disease^® '^. The high level of virulence associated with 
BVDV 2 may reflect variation within the genotype and not a general property of the 
genotype. 
Disease due to BVDV infection is usually studied in acutely infected animals. Necropsy 
of acutely infected animals demonstrates that BVDV causes lesions on various mucosal 
surfaces including nasal, oral, rumen, reticulum, lung, colon, and small intestine^ .^ 
Replication of virus following infection starts in the oronasal mucosa and the oropharyngeal 
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lymphoid tissue^ .^ Systemic spread of the virus is facilitated by infected leukocytes in the 
bloodstream and lymphoid tissues^ .^ Viral replication in infected animak has been 
demonstrated in Peyers patches, lungs, lymph nodes, spleen, adrenal gland, thymus, gastric 
mucosa, skin, kidney, neurons, peripheral leukocytes, tissue localized lymphocytes, and bone 
marrow cells of megakaryote or myeloid lineage^®'^ '^ *'^ '. A direct comparison between 
animals infected with BVDV 1 and BVDV 2 indicated viral replication occurred in the same 
cells and tissues'* .^ Antigenic variation among viral isolates may not affect tissue tropism. 
Suppression of the bovine immime system occurs following BVDV infection and, to a 
lesser degree, vaccination with live virus. BVDV infection causes a general leukopenia in 
the blood and lymphocytic depletion of the mesenteric lymph node, tonsils, spleen, and 
thymus^ .^ Replication of BVDV has been demonstrated in monocytes, platelets, aP Tcells, 
and yS T cells^®"^ '^^ . Interestingly, BVDV may not be able to replicate in B lymphocytes '^*. 
The total number of circulating lymphocytes are decreased in response to BVDV infection^  ^
and to a lesser degree to vaccination with live vinis^ .^ Infection or vaccination of cattle with 
live virus also decreases the proliferative edibilities of peripheral blood mononuclear cells 
to mitogens^^^ .^ Production of IgM and IgG by B cells in peripheral blood stimulated with 
Pokeweed mitogen is also suppressed by BVDV^ .^ The suppression of immune responses by 
BVDV probably results from the combined effects of lymphoid tissue destruction and 
cellular dysregulation. Cytopathic strains of BVDV kill cellular hosts via apoptosis by a 
signal initiated within the infected cell^ '. Apoptotic death from BVDV infection has been 
demonstrated in monocytes, CIM"  ^T cells, CDS'*" T cells, and WCl"  ^y6 T cells from 
peripheral blood as well as cultured bovine kidney and testes cells^^" .^ The mechanism of 
apoptosis induction by BVDV is through activation of ICE family proteases^  ^and appears to 
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require the presence of monocytes in in vitro culture .^ The production of immune mediators 
is also affected by infection of immune cells with BVDV. Cytopathic and noncytopathic 
BVDV infection suppresses the proliferation of bovine thymocytes in response to monocyte-
derived EL-l^ '. Production of inducible nitric oxide synthase by bone marrow macrophages 
is inhibited by noncytopathic BVDV, but not by cytopathic BVDV^ .^ Alveolar macrophages 
infected with BVDV have decreased expression of complement receptors and Fc receptors^ .^ 
Chemokine secretion and anti-microbicidal activity by neutrophils is also suppressed by 
BVDV infection^^-". 
T cell mediated immunity to bovine viral diarrhea virus 
Despite the various means of suppression induced by BVDV on the bo\ine immune 
system, protective memory responses generally occur following infection of 
immunocompetent animals. The humoral immune response is fairly well characterized. 
Cattle develop antibodies against BVDV in response to immunization with killed vaccines, 
modified live vaccines (MLV), or subunit vaccines^®. Studies with passive antibody suggest 
that antibody alone can be protective against BVDV challenge"'^ '. Correlating protection 
&om BVDV challenge with antibody levels in infected or vaccinated animals is confounded 
by the potential presence of cell mediated immime responses. 
Specific immune responses to BVDV infection have been described for T lymphocytes, 
but these responses are not well characterized. Cattle naturally or experimentally infected 
with BVDV have peripheral blood mononuclear cells (PBMC) that proliferate \^ en co-
cultured with live BVDV in vitro^^ .^ Monocytes infected with BVDV 1 induce a 
proliferative response in peripheral CD4'^  and CDS*  ^T cells from cattle seropositive for 
! 
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BVDV '^. The proliferating CD4* cells in this study also produced IL-4 in response to 
BVDV infected monocytes, while CDS"*" T cells produced IL-2 and IFNy .^ Others reported a 
lack of significant in vitro lymphocyte proliferative responses to BVDV for calves sampled 7 
days following vaccination'^ . 
The role of ganuna delta T lymphocytes in BVDV immunity has not been explored. 
Twenty five percent of the PBMCs proliferating in response to BVDV reported by Beer and 
colleagues were CD2 negative'®. This important adhesion molecule is expressed on most T 
cells, but is not expressed on B cells or on the WCl"  ^yS T cell population that predominates 
in the peripheral blood. The WCl" T cell population that is a small percentage of the y6 T 
cells in bovine blood does express the CD2 molecule as well as CDS"*"'^ . Proliferation of the 
WCrCD2'l)8''' y6 T cell subset in response to BVDV has been briefly described, but was 
viewed as an artifact interfering with CD4''^  and CDS"*" T cell measurements'^  Lymphocytes 
not labeled by Peanut agglutinin or immunoglobulin increased in number in the blood stream 
following BVDV infection of calves^ .^ Peanut agglutinin theoretically binds all T cells of 
thymic origin and circulating T cells. Could this population of responding lymphocytes be 
the CDS"''/y§T cells that are not normally abimdant in bovine blood and mature 
extrathymically? 
Cytotoxic T lymphocytes (CTL) capable of MHC restricted killing of BVDV-infected 
target cells can be isolated from peripheral blood of immune animals'*'. Natural killer cell 
activity in bovine PBMCs was not observed in animals immune to BVDV'^ . The absence of 
natural killer cell activity and the MHC restriction of the cytolytic cells in this study indicate 
that the CDS"*" T cell population probably has the primary cytotoxic role against BVDV-
infected cells. Cytolytic T ceils were also demonstrated in a mouse model of BVDV 
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infection^^. Splenic T cells from mice immunized with a genetic vaccine based on the NS3 
protein had cytotoxic activity against mouse cells infected in vitro with either genotype of 
BVDV'^ . The NS3 protein is one of the most conserved proteins among BVDV strains'', 
and may represent an important epitope for vaccine exploitation. 
The development of vaccines that completely protect against BVDV infection in herds is 
hampered by the genetic diversity of the virus. This RNA virus is a 12.5 kb pestivirus in the 
Flaviviridae family and is closely related to Border Disease Virus of sheep and Hog Cholera 
Virus of swine. The viral genome is single stranded and positive sense. Proteolytic 
processing of the one transcribed polyprotein yields the structural and nonstructural viral 
proteins'®. There is considerable diversity among the proteins encoded by genes from 
different BVDV isolates''. Both genotypes and both biotypes of BVDV may cause 
significant disease in vivo and there is currently no molecular marker to indicate the virulence 
of a strain of BVDV^^. Antibodies that neutralize BVDV are usually directed to the E2 
envelope protein® .^ This important epitope has the potential for tremendous variability 
among BVDV strains. Genetic probes directed against segments of this protein indicate a 
high degree of diversity among BVDV strains, with up to 47% heterogeneity". Antibodies 
against E2 proteins can be used to separate BVDV isolates into groups as antibodies against 
BVDV 1 E2 proteins frequently do not recognize E2 proteins from BVDV 2^*'*'. 
Despite the significant diversity observed between BVDV strains, vaccines based on one 
strain are quite often effective in preventing disease from various strains of BVDV. 
Vaccines used to immunize cattle against BVDV historically have contained cytopathic 
BVDV 1 isolates. Immunization with one strain of either killed or modified live BVDV 
generates antibodies that can neutralize the in vitro infectivity of several additional 
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strains®o;82;83 isolates neutralized in these studies with immune senmi included 
cytopathic and noncytopathic strains from both genotypes. A challenge model provides 
further support for cross protection between genotypes in response to vaccination. Heifers 
vaccinated with a modified live BVDV 1 vaccine were protected from challenge with a 
virulent BVDV 2 seven months after challenge**. Despite this evidence for cross protection, 
animals from vaccinated herds can still be infected with genetically diverse BVDV strains. 
Calves persistently infected with BVDV 2 can be bom to dams vaccinated with killed or 
MLV containing BVDV The development of calves bom persistently infected with a 
BVDV strain antigenically diverse from the vaccine strain is probably a rare event 
Persistently infected animals are critical to perpetuation of the virus^ ,^ however, and this rare 
event may represent the key to BVDV persistence in cattle herds. 
The perfect BVDV vaccine would protect against fetal or postnatal infections by diverse 
isolates of BVDV without any adverse side effects. The numerous killed and modified live 
vaccines marketed as protective against BVDV infection do not meet this standard. Fetal 
infection still occurs in herds vaccinated with killed vaccines^ .^ Modified live vaccines may 
cross the placenta^ ,^ induce mucosal disease in PI animals '^, or cause immunosuppression in 
vaccinated animals^ .^ A subunit vaccine based on the E2 protein from a BVDV 1 isolate 
protected fetuses from maternal challenge with BVDV l*', but protection from BVDV 2 
challenge was not determined. 
The degree of antigenic diversity in the immunodominant epitopes of BVDV makes it 
unlikely that a humoral immune response to one BVDV strain could generate antibodies that 
protect against all isolates of BVDV^ .^ In contrast to humoral immunity, T cell mediated 
immune responses are more likely to be directed against conserved core proteins due to 
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endogenous processing of viral particles. Modified live vaccines are much more likely to 
induce a T cell mediated immune response than are killed vaccines due the ability to access 
endogenous antigen processing pathways. The E2 surface protein is predominantly 
recognized by serum from animals vaccinated with killed BVDV vaccines'®. In contrast, 
serum from animals vaccinated with modified live BVDV vaccines predominantly 
recognizes the NS3 enzymatic protein compared to the E2 protein. The NS3 protein has a 
much higher degree of genetic conservation than the E2 protein^  ^and antibodies against the 
NS3 protein react with a broader range of BVDV isolates* .^ 
The bovine T cell responses to BVDV exposure discussed in this review represent 
preliminary investigations. Broad characterizations based on the limited observations to date 
are not possible. Exploring the roles of CD4% CDS"  ^and y5T cells in immune responses to 
BVDV immunization could be essential for designing safer and more effective vaccines. 
Immune response of cattle to bovine herpesvirus 1 
Bovine herpesvirus 1 infection of cattle 
Bovine herpesvirus 1 (BHV-1) is a DNA virus of the alphaherpesvirus family that is also 
a major cause of respiratory and reproductive disease in catde. In addition to respiratory and 
reproductive disease caused by BHV-1 alone, infection with BHV-1 is one of the most 
common predisposing factors for development of the Bovine Respiratory Disease Complex 
(BRDC)^°. BRDC accounts for approximately $640 million in losses to the cattle industry in 
the U.S.". Currently only 1 serotype of BHV-1 has been identified, but there are differences 
in virulence among strains .^ Upon infection of an animal, BHV-1 initially replicates in the 
epithelial cells at the site of entry and is distributed to other tissues via the circiilatory 
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system^ .^ Once established, BHV-1 can spread from cell to cell by intracellular bridges, anH 
is unaffected by the presence of antibody®*. 
T cell mediated immunity to BHV-1 
BHV-1 appears to be capable of replicating in many bovine cell types in the body. In 
vitro, CD4'^  cells are infected at a much higher rate than CDS"  ^or y5 T cells'' and monocytes 
are infected almost exclusively compared to dendritic cells'^ . Like BVDV, BHV-1 has a 
wide range of immunosuppressive effects on lymphocytes. Infection with BHV-1 reduces 
the total number of circulating T lymphocytes in cattle''-'® and suppresses the proliferative 
response of lymphocytes to mitogen stimulation". Production of the T cell growth factor IL-
2  ^and expression of the IL-2 receptor on T cells'®® is reduced in T cells infected with BHV-
1. Recognition of antigen by cytotoxic CDS'** T cells may also be suppressed by 
alphaherpesviruses, as expression of MHC 1 molecules is downregulated by infection'®  ^
The decrease in circulating T lymphocytes following BHV-1 infection may be related to the 
ability of this virus to induce apoptosis in peripheral blood mononuclear cells''''® .^ The 
presence of glycoprotein D in the viral envelope is necessary to signal apoptosis in cells 
infected with BHV-1 The ability of this glycoprotein to signal the cell for death is 
dependent on caspases and enhances the release of virus from infected cells'® .^ 
Despite the immimosuppressive effects of BHV-1 on lymphocytes, protective inmnme 
responses usually develop in exposed animals. Neutralizing antibodies are produced in 
response to infection or vaccination with BHV-1 and act by preventing attachment to and 
penetration of host cells by vims'*. Humoral immune responses are generally considered to 
be important for preventing infection, while cell mediated immune responses (especially 
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antibody dependent cell-mediated cytotoxicity by polymorphonuclear cells and cytotoxicity 
by monocytes/macrophages) are essential for recovery fix>m infection .^ The importance of T 
cells in recovery or protection from BHV-1 is not well defined. Lymphocytes from animals 
exposed to BHV-1 proliferate and secrete IFNy and IL-2 in response to inactivated BHV-1 in 
Lymphocytes from animals vaccinated with modified live vaccine also mount a 
proliferative response to inactivated BHV-1 in Proliferation of lymphocytes in 
response to BHV-1 antigen appears to be dependent on the presence of CIM"  ^T cells'"®. A 
range of amino acid residues from BHV-1 glycoproteins B and D have been identified that 
are important for proliferation of lymphocytes frum immunized animals'® '^'®'. The 
importance of T cell proliferation and cytokine secretion in response to BHV-1 infection is 
not well established. Production of IFNy by helper T cells likely plays a large role in 
activating the macrophages that are important to clear the infection. Cytotoxic T 
lymphocytes (CTL) are also generated in animals exposed to BHV-1 Peptides from 
the major glycoproteins of BHV-1 represent important epitopes for CTL activity i^ ainst 
BHV-1 The CTL specific for BHV-1 appear to be MHC restrictedindicating a role for 
the aP T cells. Cytotoxic CD4"  ^T cells''®, as well as CDS"*  ^T cells' *' have been described in 
animals immune to BHV-1. 
Several killed and attenuated vaccines are available for protection {gainst BHV-1, but 
none of these vaccines completely prevents infection or spread of the virus'®'. Killed 
vaccines generate protective antibodies, but the duration of immunity and the generation of 
cellular inmiime responses are not adequate' As discussed above, vaccination with 
modified live BHV-l does generate T lymphocyte responses. Antibodies against BHV-1 
have been detected as long as thirty months following modified live BHV-1 vaccination" .^ 
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Whether these antibody responses correlate with long term protection from BHV-1 infection 
has not been demonstrated, because challenge studies are usually done within a few weeks of 
vaccination. Although MLV induce protective immune responses to BHV-1, the attenuated 
vims can establish latency and can be reactivated during stress or immunosuppression' 
Determining the roles of the T lymphocyte subsets responding to BHV-1 and identifying the 
epitopes important for activating these cells wotild allow for the development of vaccines 
that can generate T cell memory without establishing latent infection. 
Conclusions 
The T lymphocytes are an important component of the protective immune response to 
viral pathogens. The roles that CD4^T cells, CD8'*"T cells, and especially y5 T cells, perform 
in protective immune responses to viruses are not well defined. Before the precise fVmctions 
of T lymphocytes in protection from viral infection can be explored, antigen specific 
responses by the different T cell subsets to viral antigens must be detected. BVDV and 
BHV-1 are two viral pathogens of cattle that would be very useful for studying T lymphocyte 
responses to infection. Both of these viruses cause major economic loss to the cattle industry 
and are not effectively controlled by vaccination. Antigen specific T lymphocytes are 
generated in animals exposed to BVDV and BHV-1 and probably have an important function 
in protective immunity to these viruses. Identification of the T lymphocyte subsets activated 
by BVDV and BHV-1 will allow for fimctional characterization of cell mediated immune 
responses to these viruses. A more rational approach to vaccine development can be taken 
once the functional activity of T lymphocyte subsets responding to BVDV or BHV-1 has 
been determined. 
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CHAPTERS. INFLUENCE OF IMMUNOLOGICAL MATURITY AND MATERNALLY 
DERIVED ANTIBODIES ON CELL MEDIATED IMMUNE RESPONSES TO 
PATHOGENS IN YOUNG CALVES 
Introduction 
Calves are bom agammaglobulinemic due to the syndesmochorial structure of the bovine 
placenta and depend heavily on ingestion of colostrum for survival'. The specific and 
nonspecific immune systems are also immature in the newborn calves, making them 
especially vulnerable to infections during the first weeks of life. The protection afforded by 
maternal antibodies, however, frequently lasts longer than the immaturity of the bovine 
immune system. Maternal antibody sometimes interferes with active immunization without 
offering protection from disease. Some calves have inadequate passive antibody levels due 
to poor colostrum ingestion or inadequate immunoglobulin status of the mother. The ability 
to stimulate an immune memory response prior to catabolism of maternal antibody would be 
very desirable. The ideal vaccination program would induce active immunity in the calf 
before the maternally derived antibodies fall below protective levels. 
Stimulating an immune response that is not affected by maternal antibody would be very 
beneficial in protecting calves from many pathogens even when maternal antibody levels are 
adequate and protective. Interference with vaccination is usually determined based on the 
presence or absence of a humoral immune response, as measured by significant changes in 
serum neutralizing antibody titers. Humoral immune responses are easy to measure, but may 
not accurately indicate the presence or absence of the cell mediated arm of the active immtme 
system. The T cell mediated immune (TCMI) response (helper T cells and cytotoxic T cells) 
to pathogens may also occur in the absence of detectable antibodies. In contrast to humoral 
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immunity, TCMI responses can be stimulated despite maternal antibody and may offer a way 
to provide protection for calves at an earlier age. In this review the immaturity of the 
neonatal bovine immime system and the effect of passively acquired antibodies will be 
discussed in reference to the effect on cell mediated immune responses to antigens. 
Immaturity of the bovine immune system 
The development of competent immune memory responses by calves starts in utero and 
varies with individual pathogens .^ The age that a young calf can produce antibody or T cell 
responses to a particular pathogen reflects the stage of maturity of immime system 
components. Due to the interconnection between effectors of the immune system, TCMI 
responses to infection or immunization are impacted by deficiencies in any immune system 
component. Cell flmction, number of cells, and levels of signaling molecules of the iimate 
and acqiiired immune system of the young calf differ firom adult animals. Hemolytic 
complement activity of newborn calves has been reported to be 84% of adult levels and the 
level of total complement components does not reach adult levels until 6 months of age .^ A 
deficiency in total complement components would reduce chemoattiaction of phagocytic 
cells to sites of infection, reduce opsonization of antigen, and lower complement mediated 
lysis of pathogens. The attraction to chemotactic stimuli is reduced in polymorphonuclear 
cells (PMNC) of young calves .^ Reduced levels of complement receptor 3 (CR3) and a 
decreased ability of CR3 to bind intracellular adhesion molecule 1 (ICAM-1) molecules on 
endothelial surfaces may explain the deficient chemotactic activity of calf PMNC '^®. The 
reduced total complement level is responsible for the decrease in phagocytic ability of 
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neutrophils seen in 0-3 month old calves, as opsonization with adult plasma returns 
phagocytic ability almost to adult levels'. 
Several antimicrobial properties of bovine neutrophils that are not related to complement 
effects are also reduced in young calves, such as the production of reactive oxygen species '^*. 
Calves may be able to compensate for the reduced antimicrobial fimction of neutrophils by 
an increase in total number of neutrophils'*' and more efficient bacterial ingestion '^* by these 
cells. Monocytes in the newborn calf also have an enhanced ability to phagocytose bacteria 
and may help compensate for reduced function of neutrophils'. The responsiveness of 
newborn human monocytes to activation by T cell derived interferon is reduced in human 
cord blood derived macrophages'". Monocytes from human infants also produce less 
interleukin 6 (IL-6)''', an effect that could dampen acute phase responses of newborns to 
infection. 
Monocytes, cytokines, and complement components of maternal origin obtained from 
colostrum ingestion may also affect the innate immune response of the newborn calf. 
Colostrum ingestion greatly improves the innate immunity of the newborn calf. The major 
improvement is due to opsonic effects on phagocytosis from immunoglobulins and 
complement components of maternal origin'*''''^ . Activation of phagocytes by a nonopsonic 
factor of colostrum has also been described but this factor has not been characterized''^ '". 
The function and distribution of cells of the specific arm of the immune system also 
differ in calves compared to cows. The number of circulating B lymphocytes is reduced in 
yoimg calves compared to adults for the first 3 to 4 weeks after birth'^ "'^ . Lymph nodes of 
newborn calves contain fewer B cells in the outer cortex region compared to cows, resulting 
in a general suppression of B cell responses to antigen'^ . Impainnents of the acquired 
immune system related to B cell deficiencies may also be due to suppression of B cell 
function, as well as decreased cell numbers. The ability of peripheral blood B cells to 
produce IgG or IgA after in vitro culture is reduced for calves for the first three weeks of life 
compared to adults'^ . Intraepithelial B lymphocytes in calves less than three months of age 
phenotypically resemble naive B cells from adults* ,^ and generate IgM, but not IgG or IgA 
responses. 
The functional impairments of B cells in young calves may be related to a decreased 
ability of the T cells to provide the cytokine signals and costimulation necessary for B cell 
activation and differentiation. In vivo distribution and function of T lymphocytes in young 
cattle and other animals also differs from adults. In calves, the number of CDAr'^  (helper T 
cells) and CDS"*" (cytotoxic T cells) cells in peripheral blood is similar to adults. The 
percentage of y5 T cells in peripheral blood is much greater in young calves compared to 
adults until approximately 90 days of age'^ . Lymph nodes of newborn calves contain a 
greater number of CEW"*" and CDS'*" T cells compared to adults, but this difference was 
reported to last only a few days". In another report, 3 to 4 week old calves had fewer CD4''' 
cells in the outer lymph node cortex and fewer CD4''^  and CDS'*' cells in the deep lymph node 
cortex compared to adiilt animals'^ . Compared to adults, the number of CD4''' and CD8  ^T 
cells in the thymus and the number of CIM*  ^T cells in the spleen of calves are greater during 
the first weeks of life''. The number of yS T in the lymph node and thymus do not differ 
between cows and calves, but are more plentiful in the spleen of calves compared to cows''. 
The distribution of T lymphocytes in the gut associated lymphoid tissue may also differ by 
age in the bovine. Newborn calves have fewer CIM"*  ^or CD8'*"T cells, and more immature B 
cells in the intraepithelial lymphocyte population of the ileum compared to older calves'^ . 
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In addition to differences in number and distribution, the function of T cells in young 
animals also differs from that of adults. The abili^  of peripheral blood T cells to proliferate 
in response to mitogens is reduced in calves for the first 2 weeks following birth'". The 
mechanistic basis for this generalized T cell suppression in cattle has not been determined. 
Vaccination protocols in hiimans that would normally generate a Thl and an adequate CTL 
response in adults frequently generate a Th2 and inefficient CTL response in neonatesThe 
Th2 bias of the neonatal immune system could be related to: the unique hormonal/cytokine 
microenvironment present at birth, differences in antigen presenting cell (APC) signaling, 
and differences in activation signals affecting T cells^°. Neonatal CIM"" T cells express dim 
isoforms of the CE>45 molecule, a phosphatase that activates tyrosine kinases in the T cell 
signaling pathways '^Cord blood CD4"  ^T cells from human infants have decreased 
activity of the tryosine kinases p56'®'' and p59'^  compared to adults .^ This suppression of 
kinase activity in the major TCR activation pathway may represent the basis for the 
generalized suppression of T cell responsiveness to mitogens and antigens by neonates. The 
reduced expression of IL-2 and IL-2 receptor in cord blood CD4* cells may also be related to 
suppressed intracellular signaling^"*. Human cord blood CIM*  ^T cells also express 
significantly less CD40 ligands (CD40 L) compared to adults .^ The CD40 L is the most 
important molecule for costimulation of B cells by helper T cells and instigates class 
switching of IgM-producing B cells. Poor costimulation by CD40 L on T cells may explain 
the delay in functional maturity of B cells for several weeks following birth. The 
mechanisms of T cell suppression discussed for human neonates may not have bovine 
counterparts. Neonatal immunity in the human differs significantly fix)m that of murine 
neonates^  ^and neither species may serve as an adequate model for cattle. 
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Effect of maternal antibody on cell mediated immune responses to vaccination 
The major immunoglobulin in colostrum is IgG, ^ ^ch has a half-life of approximately 3 
-J 
weeks . The amount of maternal antibody that a calf has to a particular pathogen during the 
first few months of life varies by the amount of colostrum ingested and immune status of the 
mother. Diuring the newborn stage, colostral antibodies protect the calf from an assault of 
pathogens that the animal may otherwise be unable to resist due to the immaturity of the 
immime system. Protection from pathogens is often directly correlated to the titer of 
maternally derived antibodies^^ '^. 
Maternal antibodies are often protective against pathogens, but they frequently inhibit 
the ability of the animal to develop an antibody response to vaccination. This interference of 
active immunization by maternal antibodies is especially a concern when antibodies of 
maternal origin do not protect against infection. Bovine respiratory sjoicytial virus (BR5V) 
and human respiratory syncytial virtis (RS V) are examples of viruses that are not neutralized 
by circulating maternal antibody '^*^  ^ Due to the impact of some of these diseases, especially 
those that affect mortality rates of children, a great deal of research is currently focused on 
alternate vaccination strategies to circumvent maternal antibody interference. The nature of 
the antigen (genetic, subimit, recombinant), the adjuvant technology used, and the route of 
administration are currently being explored as means to circumvent maternal antibody 
interference^ .^ Conventional vaccines, however, may also be able to stimulate immune 
memory in the face of maternal antibody. The development of an immune response to 
vaccination is usually measured by the presence or absence of antibodies in the blood of the 
vaccinated animal. Assays that measure antibodies detect humoral immunity, but give no 
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infonnation about T cell immunity. In general, T cell responses are assumed to occur 
concuirently with humoral responses due to the requirement for T cell help in generation of a 
humoral response. 
Suppression of himioral immunity by passive antibodies may not always extend to the T 
cell-mediated branch of the acquired immune system. Calves vaccinated against bovine 
herpesvirus 1 (BHV-1) are unable to produce a measurable humoral response to vaccination 
until maternal antibody has waned to undetectable levels^ .^ In this same report, however, 
calves vaccinated while maternal antibody levels were high demonstrated an anamnestic 
hiunoral response to BHV-1 following a later vaccination. Newborn calves vaccinated with 
BRS V also have an enhanced humoral response to a second vaccination with BRSV, 
although no humoral response was detected following the first inoculation in the face of 
matemal antibody^"*. These memory responses may reflect a helper T cell response generated 
during the first vaccination that enhanced the response to subsequent vaccination. 
Proliferating T lymphocytes specific for BHV-1 and BRSV have been demonstrated in 
vaccinated calves with matemal antibody, w^e no humoral immime response was 
detected^ 
Literature describing the effect of matemal antibody on T cell memory responses in 
cattle is limited, but research in other domestic animals and humans is available. Young pigs 
with a high level of matemal antibody to pseudorabies (PRV) develop a lymphoproliferative 
response to in vitro PRV following an intranasal inoculation^ .^ This T cell response occurred 
despite the suppressive effect of maternal antibody on development of a humoral immunity 
to PRV. A humoral response to measles by macaques is inhibited by even very low levels of 
matemal antibody although animals are protected fitim measles challenge^ .^ Protection firom 
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measles challenge was likely mediated by the generation of measles specific CTLs and 
lymphoproliferative responses to in vitro antigen reported in this study. Another study 
indicates that lymphoproliferation and cytokine secretion by T cells in response to measles 
antigen also develops in animals with high levels of maternal antibody at vaccination^ .^ An 
adenovirus study in human infants further demonstrates that T lymphoproliferative responses 
can frequently occur in the absence of humoral responses ulien maternal antibody is 
present^*. 
T cell mediated immune responses occurring in the absence of humoral immunity is well 
documented in individuals with itiatemal antibody, but does not always occur. The 
generation of specific T cells in response to malaria in mice, as well as to rabies and Sendai 
virus in dogs are inhibited by maternal antibody '^'^ . The nature of the pathogen may affect 
the ability of the animal to mount a TCMI response in the face of maternal antibody. In a 
direct comparison, maternal antibody in mice was shown to inhibit the generation of a 
cytotoxic T cell response to RS V, but not to influenza virus '^. The route of inoculation may 
also affect the ability of an individual to develop a T cell response when maternal antibody is 
circulating. Pigs with high levels of maternal antibody to PRV were imable to generate 
lymphoproliferative responses to in vitro PRV when the vaccine was given intramuscularly, 
but were able to generate a strong proliferative response when the vaccine was given 
intranasally**'. In some cases the type of immune response generated when maternal antibody 
is present may reflect individual differences. Some infants vaccinated against measles during 
times of high maternal antibody circulation developed a lymphoproliferative response to in 
vitro measles antigen with and without a himioral response, some developed a humoral 
response without a lymphoproliferative response, and some did not develop any measurable 
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immune response^ .^ The observed differences in generation of antigen specific T cells to 
viral antigen could also be related to the immunological maturity of the individual at the time 
of exposure. The increasing frequency of CTLs to HIV and RSV with age has been 
postulated to accompany the maturation of the immune response from a TH2 bias to a 
balanced Thl/Th2 response '^. Reports of inhibition of T cell responses by maternal antibody 
in the literature may be confounded by the developmental stage of the immune system. The 
ability of young animals to generate T cell responses to antigens at different developmental 
ages must first be determined in the absence of maternal antibody. 
Conclusions 
Maternally derived antibody is necessary to protect the yoimg calf from disease during 
maturation of the immune system. This passive immunity is fr«quentiy thought to interfere 
with conventional immunization in young calves based on lack of humoral inmiune 
responses. T cell mediated immune responses to immunization can occur in the absence of a 
humoral immune response when maternal antibody is present in the bloodstream. 
Stimulation of memory TCMI responses by early vaccination may represent an opportunity 
to provide earlier protection against disease in the calf. Recommendations for vaccination, 
however, will depend on more exploration of cell mediated inunune responses to various 
antigens in the face of maternal antibody. The specific roles of the different T lymphocyte 
subsets in TCMI also need to be characterized. The maturation of the TCMI response 
independent of, and affected by, maternal antibody in cattle also requires much more 
exploration before general conclusions can be drawn. 
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CHAPTER 4: IN VITRO DETECTION OF ANTIGEN SPECmC BOVINE CD4  ^CD8*, 
AND y6 T LYMPHOCYTE RESPONSES FOLLOWING VACCINATION WITH 
MODIFIED LIVE PESTTVIRUS AND HERPESVIRUS 
A paper to be submitted to Veterinary Immimology and Immunopathology 
J.M. Jones-Endsley, MJ. Quade, B. Terfaaar, and J.A. Roth. 
Abstract 
A trial was conducted to monitor T ceil subset activation by bovine herpesvirus-1 (BHV-
1) and bovine viral diarrhea virus (BVDV), and protection from BHV-1 challenge in 
vaccinated cattle. Upregulation of the high affinity interleukin 2 receptor a chain (CD25) 
was used to monitor antigen specific activation of T lymphocyte subsets CDS" ,^ and 
y5 T cells) from cattle immunized with modified live BVDV and BHV-1 vaccines. Two 
groups of fifteen animals were vaccinated with one dose of BHV-1 and BVDV genotype 1 
(BVDV 1), or one dose of BHV-1, BVDV 1 and BVDV genotype 2 (BVDV 2). The group 
receiving the vaccine with BVDV 1 was designated MLV 1 and the group receiving the 
vaccine with BVDV 1 and BVDV 2 was designated MLV 1 & 2. Six animals seronegative 
for BHV-1 and BVDV antibody and negative for BVDV virus were used as negative 
controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with 2 
doses of modified live BVDV 1 and BHV-I vaccine served as positive controls. Blood 
samples were taken from the negative control group, the positive control group, and the MLV 
1 & 2 group at 0, 3, 5, 7, 21, 35,60 and 90 days post inoculation (PI). Blood samples were 
taken from MLV 1 group at 0,21, and 90 days PL Isolated peripheral blood lymphocytes 
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&om immunized and control animals were incubated for 5 days with and without BVDV 1, 
BVDV 2, and BHV-1. Activated T lymphocytes were detected by two color flow cytometry 
using phycoerythrin labeled antibodies specific for CD25 and fluorescein isothiocyanate 
labeled antibodies specific for either CEW"*", CDS"*", or yS T cell receptor. CD4'^  T cells from 
the MLV 1 & 2 group increased expression of CD25 at 60 and 90 days PI following in vitro 
exposure to BVDV 1 and BVDV 2, and at 21, 35, 60 and 90 days PI after exposure to BHV-
1. The MLV 1 group had increased expression of CD25 on CD4"*  ^T cells after exposure to 
BVDV 1 and BHV-1 at 90 days PL CD25 expression on CD8"*" T cells increased at 35, 60 
and 90 days on lymphocytes from MLV 1 & 2 animals after exposure to BVDV 1, BVDV 2, 
and BHV-1. CDS"*" T cells from the MLV 1 group had increased expression of CD25 after 
exposure to BVDV I, BVDV 2, and BHV-1 at 90 days PI. Gamma delta T lymphocytes 
from the MLV 1 & 2 group upregulated expression of CD25 at 35, 60 and 90 days PI when 
exposed to BVDV 1 and BVDV 2, and at 21, 35, 60 and 90 days PI when exposed to BHV-1. 
The MLV 1 group had increased expression of CD25 on y5 T cells after exposure to BVDV 
1, BVDV 2, and BHV-1 at 90 days PI. The vaccinate groups did not have significantly 
(P<0.05) different expression of CD25 on any of the T cell subsets in response to BVDV 1, 
BVDV 2, or BHV-1 exposure. Vaccinates were protected from challenge with BHV-1 at 110 
days post vaccination compared to non-vaccinates. Expression of CD25 appears to be useful 
for evaluating induction of antigen specific T lymphocyte subset responses following 
vaccination. 
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Introduction 
Bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BHV-1) cause 
respiratory, enteric and reproductive diseases that result in major economic loss to the beef 
and dairy cattle industries'. BVDV viruses exist as two genotypes (BVDV 1 and BVDV 2) 
differentiated by sequences in 5' UTR  ^and two biotypes (cytopathic or noncytopathic) based 
on effects in cell culture .^ Noncytopathic (ncp) BVDV is the most common biotype isolated 
fi-om infected animals  ^and is citable of causing persistent infection in animals exposed early 
in gestation '^^ . The cytopathic (cp) biotype can cause mucosal disease in animals infected 
with a homologous ncp biotype'*®. BVDV 1 is the type commonly used as a vaccine and as a 
diagnostic test antigen while BVDV 2 has been described more recently in cattle that died of 
an acute hemorrhagic form of BVDV .^ Bovine herpesvirus 1 is a DNA virus of the 
alphaherpesvirus family that is also a major cause of respiratory and reproductive disease in 
cattle'. Vaccination with modified live BHV-1 reduces disease; however, the attenuated 
virus can establish latency and can be reactivated during stress or immunosuppression .^ 
Despite the availability of numerous modified live and killed virus vaccines, disease 
caused by BVDV and BHV-1 continues to be a serious problem in cattle. The humoral 
immune response after vaccination or natural exposure to both viruses is well 
characterized '^^ , but much less is known about the T cell mediated immune response. Cattle 
vaccinated with modified live or killed BVDV antigens develop serum antibodies that 
neutralize a broad panel of type 1 and type 2 BVDV isolates in Vaccination with 
commonly used modified live vaccine (MLV) BVDV type 1 isolates has been shown to 
protect animals fi-om challenge with virulent type 2 strains'^ "'*. However, the degree of 
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antigenic diversity in the immunodominant epitopes of BVDV makes it unlikely that one 
BVDV strain could provide an adequate humoral memory response to all isolates' '^ . In 
contrast to humoral inomunity, cell mediated immune responses are more likely to be directed 
against conserved core proteins due to endogenous processing of viral particles. In vivo 
depletion of CIM"  ^T cells extends the length of viremia in calves infected with BVDV'^ . 
Lymphocytes from animals exposed to BVDV proliferate, secrete cytokines and can have 
cytotoxic activity in response to in vitro BVDV antigen'^ *". The activation of different 
subsets of T lymphocytes in response to BVDV antigens in vitro has not been determined. 
Protective antibodies produced in response to infection or vaccination with BHV-l act 
by preventing attachment and penetration of host cells by virus .^ Antibodies against BHV-l 
have been detected as long as thirty months following vaccination^ .^ Whether these antibody 
responses correlate with long term protection from BHV-l infection has not been 
demonstrated, as challenge studies ate usually done within a few weeks of vaccination. The 
importance of T cells in recovery or protection from BHV-l is not well defined. 
Lymphocytes from animals exposed to BHV-l proliferate and secrete IFNy and IL-2 in 
response to inactivated BHV-l in vitro^K Proliferation of lymphocytes in response to antigen 
is dependent on €04"*" helper T cells although cytotoxic CD4* T and CDS"  ^T cells have 
also been described.^ ^ .^ 
Characterization of the T lymphocyte subsets responding following vaccination would 
be valuable information for optimizing vaccination strategies to protect cattle against BVDV 
and BHV-l. The a chain of the interleukin 2 receptor (CD25), which is present only on 
activated T cells, can be used to monitor T cell responsiveness to specific antigen using flow 
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cytometry^ .^ The objectives of this study were: 1) to determine if cattle vaccinated with 
modified live BVDV type 1 and/or BVDV type 2, and BHV-1, have CD4\ CD8" ,^ and yS T 
cells that become activated when exposed to genetically homologous or heterologous antigen 
in vitro and 2) to determine if modified live BHV-1 vaccines provide protective immunity at 
110 days after vaccination. 
Materials and Methods 
Animals 
Thirty-six crossbred beef steers, age 12-16 months and weighing between 270-310 kg 
were used in the study. Animals were negative for BVDV and BHV-1 based on virus 
antibody titer, virus isolation attempts, and in vitro lymphocyte responsiveness to antigen. 
Animals were randomly assigned to treatment groups; six animals served as negative controls 
while two groups of fifteen were put in separate housing and inoculated with different 
vaccines. Three previously vaccinated animals with known positive T cell responses to 
BVDV 1, BVDV 2, and BHV-1 were used as positive controls to validate the assay at each 
time point. These animals had received 2 doses of BRSV Vac-4 (Miles Inc. Shawnee 
Mission, KS ) containing modified live BVDV 1, BHV-1, parainfluenza 3 (PI3), and bovine 
respiratory syncytial virus (BRSV) approximately 7 and 5 weeks before onset of the trial. 
Vaccination 
Animals in the vaccine groups were given a 2 ml intramuscular dose in the neck on day 
0. Fifteen animals were vaccinated with Titanium 5 L5 (Agri Labs, St. Joseph, MO) 
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containing modified live BVDV 1 (C24V strain), BVDV 2 (296 Bolin strain), BHV-1, 
BRSV, PI3, and killed Leptospira bacterin (canicola, grippotyphosa, hardjo, 
icterohaemorragiae, pomona). This treatment group was designated MLV 1 & 2. Another 
group of 15 animals was vaccinated with Bovishield (Pfizer Animal Health, Exton, PA) 
containing modified live BVDV 1 (NADL strain), BHV-1, PI3, BRSV and killed Leptospira 
bacterin (canicola, grippotyphosa, hardjo, icterohaemorragiae, pomona). This treatment 
group was designated MLV 1. Six animals that were not vaccinated served as a negative 
control group. Animals were monitored immediately after injection and for the next seven 
days for adverse reactions or problems associated with vaccination. 
Challenge 
One hundred and ten days after vaccination animals in all treatment groups were 
challenged intranasally with lO'"  ^TCID50 of live Cooper strain BHV-l (obtained from 
USDA-APHIS National Veterinary Services Laboratories, Ames, L .^). Clinical signs (Table 
2) and rectal temperatures were recorded for 14 days following challenge. 
Measurement of T Cell Activation 
Antigen specific T cell subset activation was detected using a modification of a 
previously described procedure .^ Ten animals from each vaccinate group and three animals 
from the non-vaccinate group were randomly chosen to monitor in vitro T cell activation by 
BVDV and BHV-1 following vaccination. The same animals were used during all sampling 
periods. Peripheral blood mononuclear cells (PBMC) were isolated from 50 ml citrated 
blood, washed twice in Hanks balanced salt solution (HESS) without calciimi and 
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magnesium, and resuspended at 4 x 10  ^in 200 nl of RPMI media containing 2 mM L-
glutamine, penicillin (60 ng/ml), 20 mM HEPES, and 7.5 % fetal calf serum. Triplicate 
wells of PBMCs were cultured alone and with BVDV 890 (type 2), BVDV 970 (type 1), 
BHV-1, or Concanavalin A for 5 days at 39® C. BVDV type I virus was grown in bovine 
turbinate (BT) cells in McCoys 5A medium supplemented with 10% fetal bovine serum 
known to be free of BVDV virus and antibodies. Flasks of BT cells were incubated for 24 
hours and inoculated with 10  ^TCID50 of BVDV. Virus was grown for 48 hours and frozen 
at - 80°C. Culture flasks were then thawed and cell culture media centriiuged at 2,000 x g to 
remove cellular debris. BVDV type 2 and BHV-1 were grown in Maden Darby Bovine 
Kidney (MDBK) cells using a similar procedure. Viral titer of the type 1 BVDV was 10  ^
TCID50 and titer of the type 2 BVDV was lO^TCIDso. The titer of the BHV-1 was 10® 
TCID50. The virus was confirmed to be BHV-1 using fluorescent monoclonal antibody 
against BHV-1 in infected MDBK cells. The amount of viral antigen to use in the CD25 
expression assay was optimized using positive control animals. 
Following 5 days of culture, cells were washed twice with HBSS and twice with a PBS 
solution containing 0.5% BSA and 0.1% NaNs (PBS .^ The washed cells were then stained 
with murine monoclonal antibodies specific for bovine CD4 (CACTI38A), CD8 
(CACT80C), and 76 (GB21 A) T cells and a murine monoclonal antibody specific for bovine 
CD25 (CACTI 08A)(VMRD, Pullman, WA). The antibodies specific for CD4, CDS, and a 
matched isotype control were an IgGl isotype, ^ A^e antibodies specific for yS TCR and a 
matched isotype control were an IgG2b isotype. The antibody specific for CD25 was an 
IgG2a isotype. Following a 30 minute incubation at 4** C, cells were washed 4 times with 
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PBS"  ^and then stained with phycoerythrin labeled anti'IgG2a and either fluorescein 
isothiocyanate (FITC) labeled anti-IgG2b (yS and isotype control) or FITC labeled anti-IgGl 
(CD4, CDS, and isotype controlXCaltag, Burlingame, CA). After 30 minutes at 4° C, cells 
were washed 5 times in HBSS (without Ca^, Mg^, or phenol red) and fixed in 1% 
paraformaldehyde. Triplicate wells were pooled prior to coimting. 
Data Analysis 
Antigen specific T cell responsiveness to in vitro antigen was determined by flow 
cytometric analysis. A total of5,000 gated cells per sample were counted on a Becton 
Dickinson FACScan (San Jose, CA). Data are reported as an expression index, which is a 
ratio of the lymphocyte responsiveness from each animal when stimulated with BVDV 1, 
BVDV 2, or BHV-1 versus when not stimulated with antigen .^ Expression Index = (% 
stimulated T cells positive for CD25) * (mean fluorescent intensity of stimulated T cells 
positive for CD25) / (% unstimulated T cells positive for CD25) * (mean fluorescent 
intensity of unstimulated T cells positive for CD25). A Wilcoxon rank sian test was used to 
determine the level of significance of the differences between nonvaccinate and vaccinate 
responses to BVDV 1, BVDV 2, and BHV-1. Temperature data were analyzed by the Mixed 
Procedure of SAS (SAS Institute, Cary, NC). The error associated with the repeated 
measures was modeled using a first order autoregressive structure. In this analysis, a 
significant day^treatment group interaction was detected, thus means within a day were 
further assessed by a least significant difference test, in which all pairs of means within a day 
were compared. Clinical scores were assessed by the Kruskal-Wallis non-parametric test. 
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When this test revealed significant differences (P<0.05), the groups were compared by 
Dunn's procedure in an all pair-wise fashion. 
Results 
Adverse reactions to vaccination were not observed in either treatment group following 
inoculation. One animal in the MLV 1 & 2 vaccine group died at day 32 post vaccination. 
Necropsy determined the cause of death to be bloat. 
Peripheral blood CDS"* ,^ and y6 T lymphocytes from animals in all treatment 
groups responded to in vitro stimulation with Concanavalin A by substantially increasing 
expression of CD25, indicating that all lymphocytes subsets were capable of responding 
(data not shown). All three T cell subsets from positive control animals were also activated 
by BVDV 1, BVDV 2, and BHV-1 antigen (Table 1), indicating that the antigens used in the 
assay were capable of stimulating lymphocytes from positive animals. 
The CD25 Expression Index of CD4"  ^T cells incubated with BVDV 2 antigen from the 
MLV 1 & 2 vaccinate group was significantly (P<0.05) greater than non-vaccinate group 
only at day 60 (Figure 1). CD8  ^and yS T cells from the MLV 1 & 2 group were significantly 
(P<0.05) activated by in vitro incubation with BVDV 2 from 35 to at least 90 days post 
vaccination. When incubated with BVDV 1, the expression of CD25 by all T cell subsets 
from the MLV 1 & 2 group was significantly increased at the same time points as occurred 
for incubation with BVDV 2 (Figure 2). 
There were no significant (P<0.05) T cell subset differences between the MLV 1 & 2 
and MLV 1 vaccinate groups at 0,21, & 90 days when exposed to either of the BVDV 
antigens (Figure 1). An increase in expression of CD25 on any of the T cell subsets from the 
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MLV 1 group was not detected after exposure to BVDV 2 (Figure 1). When stimulated with 
BVDV 1, however, CDS"*  ^and yS T cells from the MLV 1 vaccinate group significantly 
responded (P<0.05) compared to non-vaccinates at 90 days post vaccination (Figure 2). 
Early in the trial, high background values for the lymphocytes that were not stimulated 
with in vitro antigen were a problem. The expression index is sensitive to artificial inflation 
when the backgroimd values are high. A change in fixative preparation fixim dilution of 
100% formaldehyde to dilution of a 10% solution on day 35 post vaccination seemed to 
lessen this effect. 
In response to in vitro BHV-1 antigen, CIM"  ^T cells from the MLV 1 & 2 group 
significantly increased CD25 expression compared to the non-vaccinates at 5,21, 60, and 90 
days post vaccination (Figure 3). There was a tendency (P<0.10) towards activation of 
T cells from the MLV 1 group compared to the non-vaccinate group at 21 days and a 
significant (P<0.05) response was seen at 90 days post vaccination. Compared to the non-
vaccinate group, expression of CD25 by CDS"  ^T cells in response to BHV-1 was 
significantly greater (P<0.05) at 35 to 90 days PI for the MLV 1 & 2 group. Activation of y5 
T cells for this group was significantly greater (P<0.05) at 21 to 90 days PI. Expression of 
CD25 on CDS"*  ^and y6 T cells firom the MLV 1 group was activated by BHV-1 was 
significantly greater (P<0.05) than the non-vaccinate group at 90 days post vaccination. 
Expression of CD25 on any T cell subset in response to BHV-1 exposure did not 
significantly (P<0.05) dififer between the two vaccinate groups. 
Prior to BHV-1 challenge, cattle in the non-vaccinate treatment group were verified to 
be seronegative for this antigen. Animals in all treatment groups were seronegative for 
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BHV-1 before vaccination and were clinically normal prior to challenge. Following 
challenge with virulent BHV-1 at 110 days post vaccination, animals were observed for 
clinical signs and rectal temperatures were taken daily for 14 days. Non-vaccinated animals 
had significantly higher (P<0.05) rectal temperatures from 2 to 7 days post challenge 
compared to either vaccinate group (Figure 4). There were no significant differences in daily 
mean temperature between vaccinate groups. Clinical scores of non-vaccinated animals were 
higher than vaccinates from 4 to 10 days after challei^ e (Figure 5). These differences were 
statistically significant (P<0.05) at 5,6,7, and 9 days post challenge. Severe clinical signs 
indicative of BHV-1 infection included appetite depression, anorexia, severe nasal discharge, 
and coughing. There were no significant differences in daily clinical scores between 
vaccinate groups. 
Discussion 
In this trial, T cells specific for BVDV and BHV-1 antigens were demonstrated in vitro 
following vaccination of cattle with modified live vaccines. Expression of CD25 on 
activated cells indicates that CD8"  ^and yS T cells specific for BVDV are present in cattle by 
35 days following vaccination. This is the first report of the kinetics of T cell subset 
responses to BVDV that these authors are aware of. Previous research indicates that 
cytotoxic T lymphocytes specific for BVDV are present in the peripheral blood of cattle at 2 
and 9 months post vaccination, but the responding T cell subsets were not identified". 
Lymphocyte proliferation and IFNy production have been reported at 7 weeks, but not 4 
weeks, following vaccination of mice with recombinant BVDV protein". Others reported a 
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lack of in vitro lymphocyte proliferative responses to BVDV for cattle sampled 7 days 
following vaccination with BVDV'^ . They did not test for lymphocyte responsiveness at 
later times. The kinetic responses of T lymphocyte subsets to BHV-1 in the current trial are 
in general agreement with a previous report", with the exception of positive CD8+ T cell 
responses in the current trial (discussed below). 
CDS"  ^and y5 T cells specific for the BVDV genotype homologous to the vaccine strains 
were present in cattle by 35 days and up to 90 days following vaccination. There was a 
tendency toward CDS'*" and y6 T cells specific for the BVDV genotype heterologous to the 
vaccine strain at 90 days, but the level of activation was not significant compared to non-
vaccinates. The lack of response to the heterologous genotype of BVDV represents only one 
time point (90 days after vaccination) in this study. This is in contrast to other reports 
showing in vitro lymphocyte proliferation to, and protection from challenge with, a 
heterologous BVDV genotype following vaccination'^ '*^*''. Antigen specific T cells 
generated by vaccination with BVDV 1 should protect against challenge with BVDV 2 as 
cell mediated responses to BVDV are likely to be against more conserved epitopes as 
compared to antibody responses. Interestingly, the positive control animals that were 
vaccinated twice with BVDV 1 did respond significantly to the heterologous genotype of 
BVDV (Table 1). This indicates a potential role for repeated exposure in generating T cell 
responses to the heterologous genotype of BVDV. 
The absence of a measurable CD4* response by vaccinated cattle to in vitro BVDV 
antigens of either genotype was unexpected. In vivo depletion of CD4" ,^ but not of CDS'*" and 
y6, T cells subsets has previously been shown to increase viral titers and length of viremia in 
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animals exposed to BVDV'^ . Cytokines from CD4  ^helper T cells are expected to have an 
important role in proliferation and activation of CDS"*^ and y8 T cells in vitro and in vivo. 
Although CD4* T cells did not appear to be responding to BVDV or BHV-1 in the current 
trial, there may have been a low level of activation that was not detected by the assay. 
Helper cytokines could also be secreted by CDS'*" and yS T cells^^^^; thereby allowing 
activation and proliferation of these T cell subsets without the help of T cells. The 
positive control animals in this study, which received two doses of modified live vaccine, did 
have CD4'*" T cells that were significantly activated by BVDV (Table 1). Antigen specific 
CD4"  ^cells are likely generated by vaccination with modified live BVDV, but may require 
two doses to be measurable in peripheral blood. 
In the current trial, vaccination with modified live BHV-1 generated measurable antigen 
specific CD4'^ , CDS"*" and y6 T cells in the peripheral blood of cattle. This is the first report 
where live BHV-1 has been successfiilly used in vitro to stimulate activation and 
proliferation of antigen specific T cells. BHV-1 preferentially infects CD4'^  cells compared 
to CD8"  ^and y6 T cells, and normally induces apoptosis in CD4"*  ^T cells '^^ .^ Use of live 
BHV-1 induces cytopathic effects in cell culture, normally prohibiting the measurement of T 
cell responses. Stimulation of PBMC firom cattle vaccinated with MLV BHV-1 with a killed 
BHV-1 antigen has been shown to activate CD4'^  and y6 T cells, but not CD8+ T cells .^ 
The BHV-1 used in the current trial was a laboratory strain that had been passaged in vitro 58 
times and may have had reduced virulence and ability to induce apoptosis. 
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The roles of CD4"*  ^and CD8"*" cells in control of infectious disease of cattle have been 
more thoroughly examined than the roles of y5 T cells. These subsets would be expected to 
function as helper (CIM"*) and cytotoxic (CD8"*  ^T cells in controlling BVDV and BHV-1 
infections in cattle, as described for other viral infections. In the current trial, y5 T 
lymphocytes specific for BVDV and BHV-1 were detected following vaccination of cattle 
with a single dose of modified live vaccine. This subset had a very high level of activation, 
but could potentially include CD8" /^y6 double positive T cells. Cattle have a subset of y5 T 
ceils that also express CDS* ,^ but this population is sparse in peripheral blood^°. The role that 
activated y5 T cells specific for BVDV or BHV-1 has in protection from these viruses is 
imclear. Gamma delta T cells have been demonstrated to act as antigen presenting cells and 
cytotoxic T lymphocytes in cattle^and as a helper T cell in mice^^^ .^ Since the precise 
role of y5 T cells in cattle and other species is not well defined, the biological significance of 
antigen specific y5 T cells following vaccination is unknown. 
Conclusion 
This research is an important step towards understanding the roles of the different T 
lymphocytes in development of a T cell mediated immune response following vaccination in 
cattle. Two color flow cytometric analysis of CD25 expression on T cell subsets appears to 
be a useful method for evaluating induction of antigen specific T lymphocytes following 
vaccination BVDV and BHV-1. Vaccination of cattle with one dose of modified live BVDV 
1 or 2 generates detectable antigen specific CD8  ^and y§ T lymphocyte responses, but not 
CD4  ^T lymphocyte responses, to a homologous genotype of BVDV in vitro. Vaccination of 
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cattle with modified live BHV-1 generates antigen specific CIM"*", CD8* and yd T lymphocyte 
responses to BHV-1 virus and protects animals from challenge with virulent virus. 
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Figure 1. Expression of IL2ra chain (CD25) on T lymphocyte subsets following 5 days of i/i 
virro exposure to live BVDV 2 strain 890. *^<0.05, **^<0.01; level of statistical 
significance between vaccinate and non-vaccinate values (mean + SEM). 
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Table 1. Expression of CD25 on T lymphocyte subsets from positive and negative control animals 
in response to in vitro antigen. 
CD4^T cells CD8^T cells y8T cells 
Positive* Negative** Positive Negative Positive Negative 
BVDV1 13.84 ±2.65 1.61 ±0.32 15.35 + 3.38 1.58 + 0.49 22.09 + 4.77 3.23 + 0.71 
BVDV2 12.20 + 2.55 3.91 +0.98 11.81 +2.34 2.48 + 0.85 18.58 + 4.71 4.85 + 0.98 
BHV-1 32.83 + 2.35 2.91 +0.50 23.46 + 4.94 1.89 + 0.36 43.30 + 8.91 5.12 + 0.81 
*Mean expression index (+SEM) from three animals vaccinated 7 and 5 weeks before the trial 
started with a MLV containing BVDV I. 
**Mean expression index (+SEM) from three non-vaccinated animals. 
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Table 2. Description of clinical score assignments for challenge with BHV-1. 
Depression Score 
Normal 0 bright, alert 
eyes bright 
ears erect 
chew cud 
curious, attentive 
stays with group 
stretches back muscles, hind legs when stands up 
licks nostrils frequently 
Mild 1 ears droop slightly 
rarely stands alone 
licks nostrils occasionally 
tries to stay with group 
difficult to comer or nearly impossible to catch in corral 
Moderate 2 walks slowly 
lethargic 
stands alone for prolonged periods 
sometimes stands with head low 
easy to comer, but would be difficult to catch 
Severe 3 iminterested in environment 
very lethargic, pathetic 
stands with head lowered most of the time 
a "struggler" 
lies in sternal recumbency frequently 
often recumbent, reluctant to stand but can stand when 
encouraged 
easy for one person to catch 
Sickness Score 
0 healthy animal 
no clinical signs 
no treatment required 
1 sick animal, animal would be treated 
this is the severity of disease at which the animal should first be 
noticed as sick and treated 
recovery would be expected with appropriate therapy 
2 obviously sick animal, would be treated 
obvious clinical signs 
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Table 2 (cont'd) Description of clinical score assignments for challenge with BHV-1. 
Sickness Score (cont'd) disease is now serious, animal should have been treated before 
disease progressed to this point 
recovery would not be certain 
3 very sick animal, disease very serious 
severe clinical signs 
recovery unlikely even with ther^y 
Nasal Discharge Score 
Seroxis 1 
2 
3 
Clear Discharge - confined to nares 
Clear Discharge - outside of nares but confined to muzzle 
Clear Discharge - streaming or dripping from muzzle 
Mucus 2 
4 
6 
Off white, thick discharge - confined to nares 
Off white, thick discharge — outside of nares but confined 
to muzzle 
Off white, thick discharge — streaming or dripping from 
muzzle 
Mucopurulent 3 
6 
9 
Yellow-green, thick discharge - confined to nares 
Yellow-green, thick discharge - outside of nares but confined 
to muzzle 
Yellow-green, thick discharge - streaming or dripping from 
muzzle 
Blood Tinged 3 Any discharge containing a significant amount of blood prior to 
swabbing 
Ocular Discharge Score 
Serous 1 Clear running fluid external to the eye, running down face 
Mucus 2 Significant off >^4iite discharge in the eye or running down 
the face 
Mucopurulent 3 Significant yellow-green thick discharge in the eye or running 
down the face 
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Table 2 (cont'd) Description of clinical score assignments for challenge with BHV-1. 
Nasal Mucosa Lesion Score 
Normal 0 No lesions present 
Mild 1 Erythema of mucosa 
Moderate 2 1 to 5 non-coalescing plaques 
Severe 3 > 5 or large coalescing plaques 
Rapid Respiration Score 
Normal 0 Normal respiration 
Mild 1 >35 but <50 breaths/minute 
Severe 2 >50 breaths/minute 
Diarrhea Score 
Normal 0 solid to semi-solid stool 
Mild 2 loose, imformed stool 
Moderate 4 watery stool 
Severe 6 bloody or blood-tinged watery stool, discolored 
Couehine Score 
Normal 0 0 or 1-2 independent coughing episodes 
Mild 1 3-5 coughing episodes 
Severe 2 > 5 coughing episodes 
Anorexia Score 
Normal 0 shows interest in feed, eats 
Mild 1 shows interest in feed, does not eat 
Moderate 2 no interest, no eating 
Severe 3 no eating, gaimt, dehydrated 
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CHAPTER 5. IMMUNE RESPONSE IN CATTLE VACCINATED WITH TWO 
GENOTYPES OF KILLED OR LIVE BOVINE VIRAL DIARRHEA VIRUS 
A paper to be submitted to Agrilabs 
J.M. Jones-Endsley, B. Terfaaar, and J.A. Roth. 
Abstract 
Forty-six cattle were used in a trial to determine if antigen specific T lymphocytes 
specific for bovine herpesvirus-1 and two genotypes of bovine viral diarrhea virus could be 
measured following immunization with modified live or killed vaccine. Four groups of 9 
cattle were vaccinated with either: 1 dose of modified live vaccine (MLV) containing BHV-1 
and BVDV genotype 1 (BVDV 1), 1 dose of MLV containing BHV-1, BVDV I and BVDV 
genotype 2 (BVDV 2), 2 doses of killed vaccine containing BHV-1 and BVDV 1, or 2 doses 
of killed vaccine containing BHV-1, BVDV 1 and BVDV 2. One group of 9 animals was 
not vaccinated and served as negative controls. Prior to vaccination all animals were 
sampled for lymphocyte responsiveness to in vitro antigen and then also sampled at 4, 8,12 
and 16 weeks post vaccination. Peripheral blood mononuclear cells from immimized and 
control animals were incubated in vitro for 5 days with and without BHV-1, BVDV 1, and 
BVDV 2. Activated T lymphocytes were detected by two color flow cytometry using 
phycoeiythrin labeled antibodies specific for CD25 and fluorescein isothiocyanate labeled 
antibodies specific for either CD4"* ,^ CD8" ,^ or the yd T cell receptor. Calves were challenged 
with virulent type 2 BVDV (strain 890) 5 months after vaccination and monitored for clinical 
signs and changes in white blood cell counts. All vaccinates had antibodies to BHV-1, 
BVDV 1 and BVDV 2 at 90 and 140 days post vaccination and demonstrated an anamnestic 
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BVDV antibody response to both genotypes following challenge with BVDV 2. BVDV 
specific CD4'*", CD8"*", and yS T cells were not detected following vaccination. Following 
BVDV 2 challenge, white blood cell counts were less depressed in the two modified live 
vaccinate groups as compared to the groups which received either killed vaccine or no 
vaccine. The T cell responses in all groups and the response to BVDV 2 challenge were 
atypical in this experiment, causing the results to be difficult to interpret 
Introduction 
Bovine viral diarrhea virus causes major economic loss to cattle producers due to 
respiratory, reproductive, and enteric disease'. Several attenuated or inactivated vaccines are 
available for protection against BVDV infection, but the efficacy of these vaccines is 
frequently debated. Safe  ^is a concern with attenuated vaccines due to immunosuppressive 
properties of the vaccine antigen  ^and the possibility of congenital transmission of the live 
virus''. Inactivated vaccines can be used in pregnant animals and there is no concern for 
transmission of the vaccine virus. Although safety is not a concern with inactivated vaccines, 
protection from diverse strains of BVDV may be inadequate in vaccinated herds of cattle .^ A 
broad range of neutralizing antibodies to BVDV are produced by animals vaccinated with an 
inactivated  ^or an attenuated BVDV vaccine^* .^ It may not be accurate to correlate a broad 
range of neutralizing antibody titer to protection from all field isolates of BVDV. There is 
considerable antigenic diversity in the immunodominant E2 glycoprotein '^^  and persistent 
BVDV infections have been demonstrated in herds vaccinated with either inactivated or 
attenuated vaccine^*'®. 
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Most attenuated and inactivated vaccines are made with BVDV 1 as the vaccine 
antigen. Cattle vaccinated with a type 1 strain may not be protected from infection with the 
more virulent type 2 strains that have recently been characterized''. Animals vaccinated with 
a modified live BVDV 1 may be protected from BVDV 2 challenge'^ *'^ . One report 
indicates that animals vaccinated with a modified live vaccine BVDV 1 vaccine may also be 
susceptible to BVDV 2 disease'". Animals vaccinated with an inactivated BVDV 1 are also 
susceptible to BVDV 2 infection*. 
Successful vaccination against BVDV may be significantly advanced through a 
greater understanding of the T cell response to vaccination. Cell mediated immune responses 
are generally directed against more conserved viral epitopes and may not be as affected by 
the genotype or strain of the virus. Cattle vaccinated with modified live vaccine have 
detectable BVDV specific CD4'*', CDS* and y5 cells following vaccination'*. Antigen 
specific responses of individual T cell subsets from animals vaccinated with an inactivated 
vaccine have not been determined. The objective of the current trial was to determine if 
antigen specific CIM" ,^ CDS*, and yS T lymphocytes specific for bovine herpesvirus-land 
nvo genotypes of bovine viral diarrhea virus could be measured following immimization with 
modified live or killed vaccine, and to compare their efScacy in preventing clinical signs 
after challenge with BVDV 2. 
Materials and Methods 
Animals 
Forty-six crossbred beef heifers, age 16 months and weighing approximately 3SS kg 
were used in this study. Animals were negative for BVDV and BHV-1 based on virus 
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antibody titer and virus isolation attempts. Groups of 9 animals were randomly assigned to 
one of 5 treatment groups: 1 group of non-vaccinated controls and 4 vaccinate groups. One 
previously vaccinated animal with known positive T cell responses to BVDV 1, BVDV 2, 
and bovine herpesvirus 1 (BHV-1) was used as a positive control to validate the assay at each 
time point. This animal had received 3 doses of BRSV Vac-4 (Miles Inc. Shawnee Mission, 
KS ) containing modified live BVDV 1, BHV-1, parainfluenza 3 (PI3), and BRSV 
approximately 10, 9, and 1 months before the onset of the trial. In order to asses fetal 
protection due to vaccination, all heifers were synchronized for breeding two months after 
vaccination using IN_SYNCH® (dinoprost tromethamine) and co-mingled with three BVDV 
negative bulls. Pregnancy was confirmed by ultrasound at ^ proximately 2 months gestation. 
Thirty six animals were confirmed pregnant: 6 Bovishield vaccinates, 5 Cattlemaster 
vaccinates, 8 non vaccinates, 9 Titanium vaccinates, and 8 Virashield vaccinates. 
Vaccination 
The nine animals in each of the four vaccinate groups were given a 2 ml 
intramuscxilar dose in the neck on day 0. Group 1 was vaccinated with Titaniiim® 5 L5 
(Agri Labs, SL Joseph, MO) containing modified live BVDV 1 (C24V strain), BVDV 2 (296 
Bolin strain), BHV-1, BRSV, PI3, and killed Leptospira bacterin (canicola, grippotyphosa, 
hardjo, icterohaemonagiae, pomona). Group 2 was vaccinated with Bovi-shield® 4 + LS 
(Pfizer Animal Health, Exton PA) containing modified live BVDV 1, BHV-1, PI3, and killed 
Leptospira bacterin (canicola, grippotyphosa, hardjo, icterohaemorragiae, pomona). Group 3 
was vaccinated with Virashield® 5 + L5 (Grand Laboratories, Larchwood, lA) containing 
killed BVDV genotype 1 & 2, BHV-1, BRSV, and PI3, and killed Leptospira bacterin 
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(canicola, grippotyphosa, hardjo, icterohaemonagiae, pomona). Group 4 was vaccinated 
with Cattiemaster® 4 +L5 (Pfizer Animal Health, Exton, PA) containing killed BVDV 1, 
BHV-1, BRSV, and PI3, and killed Leptospira bacterin (canicola, grippotyphosa, hardjo, 
icterohaemorragiae, pomona). Group S was not vaccinated. Animals were monitored 
immediately after injection and for seven days for adverse reactions or problems associated 
with vaccination. 
Challenge 
Calves were challenged intranasally with BVDV genotype 2 (strain 890 NADC) at 5 
months post vaccination. Clinical signs (depression, respiratory distress, nasal discharge, 
nasal lesions, ocular discharge, loss of £q)petite, and coughing) and rectal temperatures were 
recorded for 14 days following challenge. The scoring system used to determine clinical 
signs is described in Table 1. Total and differential white blood cell and platelet counts were 
also analyzed by the Iowa State University Veterinary Clinical Pathology Laboratory (Ames, 
I A) every other day for 14 days following challenge. 
Measurement of Humoral Immune Response 
Serum neutralizing antibody titers were determined by the Iowa State University 
Veterinary Diagnostic Laboratory (Ames, lA). The titer of BVDV type 1 antibodies was 
determined using the Singer isolate and BVDV type 2 antibodies were determined using the 
125c isolate. 
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Measurement of T Cell Mediated Immune Response 
Antigen specific T cell subset activation was detected using a modification of a 
previously described procedure'^. Animals in all treatment groups were sampled for in vitro 
T cell responsiveness at 0, 4, 8 and 12 weeks following vaccination. Due to the large number 
of animals, the animals were sampled over two consecutive days at each time period. One 
half of each treatment group was sampled on the first day and the other half sampled on the 
second day. The positive control animal was sampled every day to monitor the assay. 
Peripheral blood mononuclear cells (PBMC) were isolated from 50 ml citrated blood, washed 
twice in Hanks balanced salt solution (HESS), and resuspended at 4 x 10  ^in 200 ^ 1 of RPMI 
media containing 2 mM L-glutamine, penicillin (60 ^ g/ml), 20 mM HEPES, and 7.5 % fetal 
calf serum. Triplicate wells of PBMCs were cultured either alone or with BVDV 890 (type 
2), BVDV 970 (type 1), BHV-1, or Concanavalin A for 5 days at 39® C in a 5% CO2 
atmosphere. BVDV 970 virus was grown in bovine turbinate (BT) cells in McCoys 5A 
medium supplemented with 10% fetal bovine serum known to be free of BVDV virus and 
antibodies. Flasks of BT cells were seeded for 24 hours and incubated with 10  ^TCID50 of 
BVDV 970. The flasks were inoculated for 48 hours, then frozen at - 80®C. Culture flasks 
were then thawed and cell culture media centrifiiged at 2,000 x g to remove cellular debris. 
BVDV strain 890 and BHV-1 were grown in Maden Darby Bovine Kidney cells using a 
similar procedure. Viral titer of BVDV strain 970 was lO' TCID50 and titer of BVDV strain 
890 was 10  ^TCID50. The titer of the BHV-1 was IO'TCIDso- The amount of viral antigen to 
vise in the CD25 expression assay was optimized using positive control animals. 
Following the 5 days of ciilture, cells were washed twice with HBSS and twice with a 
PBS solution containing 0.5% BSA and 0.1% NaNs (PBS" .^ All wash steps were performed 
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using an 8 channel plate washer with gravity flow. The washed cells were then stained with 
murine monoclonal antibodies specific for bovine CD4 (CACTI38A), CDS (CACT80C), or 
y5 TCR (GB21A) T cells and an antibody specific for CD25 (CACTI 08A). The antibodies 
specific for CD4, CDS, and a matched isoQpe control were an IgGl isotype. Antibodies 
specific for y6 TCR and a matched isotype control were an IgG2b isotype. The antibody 
specific for CD25 was an IgG2a isotype. Following a 30 minute incubation at 4° C, cells 
were washed 4 times with PBS*  ^and then stained with phycoerythrin labeled anti-murine 
IgG2a and fluorescein isothiocyanate labeled anti-murine IgG2b (y8 and isotype control) or 
anti-murine IgGl (CD4, CDS, and isotype control). The murine antibodies specific for 
bovine CD4, CDS, and yS TCR were purchased from VMRD (Pullman, WA) and the 
matched isotypes and fluorescently labeled secondary antibodies were purchased from 
CALTAG (Burlingame, CA). After 30 minutes at 4® C, cells were washed 5 times in HBSS 
without phenol red and fixed in 1% paraformaldehyde. Triplicate wells were pooled prior to 
analysis by flow cytometry to insure that cell numbers were adequate. 
Data Analysis 
Antigen specific T cell responsiveness to in vitro antigen was determined by counting a 
total of 5,000 cells on a Becton Dickinscn FACScan (San Jose, CA) for flow cytometric 
analysis. Data are reported as an expression index, ^ ^ch is a ratio of the lymphocyte 
responsiveness from each animal when stimulated with BVDV 1, BVDV 2, and BHV-1 
compared to lymphocyte responsiveness from each animal when not stimulated with 
antigen'^ . Expression Index = (% stimulated T cells positive for CD25) • (mean fluorescent 
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intensity of stimulated T cells positive for CD25) / (% unstimulated T cells positive for 
CD25) • (mean fluorescent intensity of unstimulated T cells positive for CD25). Data from 
expression index, antibody titer, white blood cell counts, temperature change, and clinical 
sign measurements were analyzed by ANOVA using the general linear model procedure of 
S AS (Cary, N. Carolina). Effects of treatment were considered significant at P<0.05. There 
were no differences in post vaccination response over time, so post vaccination data was 
pooled and analyzed as repeated measures using the type III error term. 
Results 
Himioral Immime Responses 
Adverse reactions to vaccination were not observed in any of the treatment groups 
following inoculation. When tested for antibody against BVDV 2, animals in the Bovishield, 
Titaniimi, and Virashield groups were positive at 90 and 140 days post vaccination (Figure 
1). Animals in the Cattlemaster group did not have demonstrable SN antibody to BVDV 2 
following vaccination. Following challenge with BVDV 2, the antibody titer of all 
vaccin£.tes indicated a similar anamnestic response (Figure 1). All vaccinates had antibody to 
BVDV 1 at 90, 140, and 155 days post vaccination, while nonvaccinates did not have 
antibody (Figure 2). At 90 and 140 days post vaccination, the Bovishield, Titanium, and 
Virashield vaccinates had significantly (P<0.05) greater antibody titers to BVDV 1 than 
animals in the Cattlemaster group (Figure 2). When tested after challenge with BVDV 2, all 
vaccinates had a significantly (P<0.05) greater antibody response to BVDV 1 than the non-
vaccinated group, indicating an anamnestic antibody response (Figure 2). Interestingly, the 
anamnestic response of the Cattlemaster vaccinates to BVDV 1 was significantly (P<0.05) 
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greater than the other vaccinate groups (Figure 2). At 90,140 and 155 days following 
vaccination the nonvaccinates did not have antibody to BHV-1 (Figure 3). Vaccinates 
receiving Bovishield, Titanium, and Virashield had a BHV-1 antibody response that was 
significantly (P<0.05) higher than nonvaccinates at all time points (Figure 3). Animals 
vaccinated with Cattlemaster, however, had an antibody response to BHV-1 that was 
significantly (P<0.05) different from nonvaccinates at 90, but not at 140 and 155, days post 
vaccination (Figure 3). 
T Cell Mediated Immune Responses 
Peripheral blood CDS'*", and yS T lymphocytes from animals in all treatment 
groups responded to in vitro stimulation with the mitogen Concanavalin A by substantially 
increasing expression of CD25, indicating that all lymphocytes were capable of responding 
(data not shown). In response to in vitro BVDV 2, expression of CD25 on CIM"  ^(Figure 4) 
and CD8  ^(Figure 5) T cells from vaccinates did not increase compared to non vaccinates 
following vaccination. Expression of CD25 on y5 T cells (Figure 6) prior to vaccination was 
significantly (P<0.05) greater for the nonvaccinates than for animals in the Cattlemaster or 
Virashield groups. Following vaccination, the nonvaccinates, the Bovishield vaccinates, and 
the Titanium vaccinates had significantly greater CD25 expression by yS T cell than did the 
Cattlemaster or Virashield vaccinates. Although statistically significant, the values for CD25 
expression by all the T cell subsets in response to BVDV 2 were generally low. All T cell 
subsets from the positive control animal responded well to in vitro BVDV 2, validating the 
activity of the assay. 
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CD4  ^(Figure 7) and CDS"  ^(Figure 8) T cells from all treatment groups failed to 
increase CD25 expression when incubated in vitro with BVDV 1. The y6 T cells (Figure 9) 
from the Bovishield vaccinates were significantly (P<0.05) activated by BVDV 1 prior to 
vaccination, compared to the nonvaccinates and the Titanium and Virashield vaccinates. 
Following vaccination, animals in the Bovishield group had greater expression of CD25 by 
y5 T cells compared to all other treatment groups. The detection of CD25 expression in all T 
cell subsets from the positive control animal indicated that the assay was capable of detecting 
activation of T cells by in vitro BVDV 1 antigen. 
When stimulated with BHV-1 antigen in vitro, expression of CD25 by CD4* (Figure 
10), CD8"  ^(Figure 11) or y8 (Figure 12) T cells was not different for vaccinates compared to 
nonvaccinates before or after vaccination. There were occasional significant differences 
between vaccinate groups, however, the importance of these differences is questionable since 
the vaccinate groups were never significantly different from the non-vaccinated group. A 
high level of expression by the positive control animal indicated that the assay was capable 
of detecting activation of T cells in response to BHV-1. 
Leukogram 
Two to six days following challenge with virulent BVDV 2, the total white blood cell 
(WBC) count (Figure 13) decreased for animals in the nonvaccinate, Cattlemaster, and 
Virashield groups. The Bovishield and Titanium vaccinates had significantly (P<0.05) 
higher WBC counts than Virashield or nonvaccinate groups at 4 days post challenge and 
higher counts compared to all groups at 6 days postchallenge. By 8 days postchallenge the 
WBC counts were returning to prechallenge levels for all treatment groups, with the 
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Bovishield group still having a higher count than all other treatments. Neutrophil levels 
returned to prechallenge levels more quickly for the Bovishield group, except compared to 
the Titanium group (Figure 14). Lymphocyte levels in the Bovishield and Titanium groups 
returned to normal levels at six days and were significantly (P<0.05) higher than the other 
treatment groups (Figure 15). Monocyte numbers (Figure 16) fluctuated for all groups 
following challenge. However, there may have been important differences between the 
modified live vaccinates and killed or non-vaccinates from 4-8 days post challenge. There 
were no significant (P<0.05) differences in hemoglobin concentration (Figure 17) among 
groups, except for a greater concentration in the Cattlemaster group at 2 days after challenge. 
Platelet coimts (Figure 18) also decreased from 0-6 days post challenge for all groups except 
Titanium. At 14 days, however, the platelet coimt for the nonvaccinates was significantly 
higher than the Bovishield or Titanium groups. In general, eosinophil counts were greatest 
for the Bovishield groups and least for the nonvaccinate group from 6-12 days post challenge 
(Figure 19). Basophil counts (Figure 20) also dropped by 4 days post challenge and in 
general seemed to recover more quickly for the Titanium group, and possibly the Bovishield 
group, from 6-8 days post challenge. The relatively low nimibers of monocytes, eosinophils, 
and basophils in the blood make observed changes difiScult to interpret. 
Clinical Response 
At 5 months after vaccination all treatment groups were challenged with virulent type 
2 BVDV and monitored for 14 days. Animals in the Cattlemaster group had a significantly 
higher temperature (Figure 21) prior to challenge compared to nonvaccinates. Four days 
after challenge the Cattlemaster group had a higher mean temperature than the nonvaccinates 
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as well as the Bovishield and Viiashield groups. At 5 and 6 days after challenge, all 
treatment groups exhibited a temperature increase, but there were no differences among 
treatment groups. By seven days post challenge the mean temperatures for all groups started 
to decline, with the Bovishield and Titanium vaccinates temperature lower than that of the 
Cattlemaster group and the nonvaccinates. At eight days post challenge the nonvaccinates 
still had a higher temperature than ail vaccinate groups except Virasheld. Interestingly, at 10 
days postchallenge the mean temperature of the nonvaccinate and Viiashield groups dropped 
to a level significantly (P<0.05) below the other treatment groups. At 14 days postchallenge 
the mean temperature of the Cattlemaster vaccinates rose to a level that was significantly 
(P<0.05) above the Virashield and nonvaccinate level. 
The clinical scores of animals in all treatment groups remained low until 8 days 
following challenge (Figure 22). By 9 days clinical signs were detected in all treatment 
groups with the scores of animals in the Bovishield group being significantly higher than 
scores of the nonvaccinate or Cattlemaster group. At eleven days, the scores of the 
Bovishield vaccinates were still significantly (P<0.05) higher than the nonvaccinates, but not 
the other vaccinate groups. 
Discussion 
All cattle developed a humoral immune response to BHV-1, BVDV 1, and BVDV 2 
following vaccination. This included a memory response as indicated by the substantial 
boost in antibody titer following challenge with BVDV 2. Groups vaccinated with either 
killed (Virashield) or MLV (Titanium) type 2 BVDV responded to vaccination with a higher 
antibody titer to BVDV 2 than groups vaccinated with vaccines containing only BVDV 1 
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(Bovishield or Cattlemaster). In general, T cell responses of vaccinates and nonvaccinates 
were not measurable following vaccination. This result was unexpected since CD4+, CD8+, 
and y5 T cell responses to BHV-1 and CD8+ and y6 T cell responses to BVDV 1 and BVDV 
2 have been demonstrated following vaccination with Bovishield and Titanium''*. The 
positive control animal upregulated expression of CD25 in response to all antigens, and 
lymphocytes from the experimental animals were activated by the mitogen concanavalin A. 
The positive y5 T cell response of some vaccinate and nonvaccinate animals to BVDV may 
be more related to a prevaccination memory response than to an effect of vaccination. These 
animals may have had T cell memory to BVDV prior to onset of the trial, despite negative 
antibody titers to BVDV. Calves exposed to BVDV while they have high maternal antibody 
titer from colostrum can develop T cell memory without a detectable antibody titer''. The T 
cells responses of the Virashield group were often significantly lower (P<0.05) than 
nonvaccinates and other vaccinates in response to BVDV and BHV-1. An unknown disease 
or stress factor unrelated to vaccination may have led to an immunosuppression of the T cell 
responses during the sampling periods. 
The changes in white blood cell (WBC) count following challenge with virulent 
BVDV 2 indicate that the MLV vaccines were more effective than killed vaccines in 
preventing a decrease in white blood cell coimt subsequent to viral exposure. Animals from 
all treatment groups demonstrated a slight fever at 5 and 6 days post challenge, but it was not 
clear if this was an effect of BVDV challenge or an unrelated factor. While there was no 
protective effect of vaccination indicated by the temperature data, the low level of fever in all 
treatment groups suggests a decreased susceptibility to BVDV infection. The clinical score 
data also suggests that vaccinated animals were not protected from BVDV compared to non-
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vaccinated animals. In this study, the drop in WBC counts and increase in temperature 
following challenge correlates with other reports of challenge with BVDV strain 890'^ "'®. 
The time frame for clinical signs following challenge is delayed in the current trial compared 
to the previous reports and does not correlate as well with changes in temperature and WBC 
counts. It is possible that the clinical scores in this trial are indicative of an unknown 
infectious disease. 
The results &om the current trial are difBcult to interpret and the authors do not have 
a high level of confidence in the data. The humoral immune response to vaccination was as 
expected, but the inability to detect T cell mediated immime responses or to generate serious 
infection with challenge was unexpected. Several animals had an apparent memory T cell 
response to several antigens prior to vaccination. On an individual basis, though, these 
responses were not well correlated to post vaccination responses. One possible explanation 
for the lack of detectable T cell responses is poor performance of the assay during this trial. 
The consistent detection of activated T cell from the positive control animal indicates that 
poor assay performance was imlikely. Another possibility is a general immunosuppression in 
the treatment animals. The lymphocytes from all animals were activated by Concanavalin A, 
but differences in CD25 expression between experimental groups and positive control 
animals in response to Concanavalin A were not evident The CD25 expression assay used 
in this trial was optimized for stimulation with BVDV and BHV-1, however, and not 
concanavalin A. Another possible factor contributing to the lack of detectable T cells 
activated by antigen is transportation of the blood samples. The positive control animals 
were housed within walking distance of the laboratory while the experimental animals were 
housed an hour away. The effects of transportation and storage of lymphocytes prior to use 
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in the CD25 expression assay needs to be detennined. The low level of response by the 
nonvaccinates to BVDV 2 challenge was also unexpected. The BVDV 2 890 strain is a 
highly virulent isolate and usually causes significant disease in unprotected animals'^  The 
lack of serious disease in nonvaccinates in the current trial could be due to a problem with 
the challenge inoculum. All groups did have an increase in antibody titer after challenge, 
indicating that the challenge virus probably replicated in the challenged animals. Two other 
unknown factors that could have played roles in the current trial were the hormonal therapy 
used to synchronize animals for breeding, and the effect of subsequent pregnancy. A few 
animals did not become pregnant, however, the experimental design did not allow for 
statistically valid comparisons between pregnant and nonpregnant animals in each treatment 
group. Overall, we were unable to draw any conclusions from this trial regarding the roles of 
different T cell subsets following vaccination with modified live or killed vaccines. 
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Figure 1. Geometric mean antibody titer (log2) to BVDV 2 following vaccination and 
following challenge with BVDV 2 at 140 days post vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 2. Geometric mean antibody titer (logz) to BVDV 1 following vaccination and 
following challenge with BVDV 2 at 140 days post vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 3. Geometric mean antibody titer (logz) to BHV-1 following vaccination. 
* Superscript notation indicates significant treatment differences of P<O.OS compared to 
nonvaccinate group. 
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Figiire 4. Expression of CD25 on CD4"  ^T lymphocytes in response to in vitro BVDV 2 
antigen. 
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figure 5. Expression of CD25 on CDS"  ^T lymphocytes in response to in vitro BVDV 2 
antigen. 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Niimber of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 6. Expression of CD25 on 78 T lymphocytes in response to in vitro BVDV 2 antigen, 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 7. Expression of CD25 on CEM"*" T lymphocytes in response to in vitro BVDV 1 
antigen. 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > S. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 8. Expression of CD25 on CDS"  ^T lymphocytes in response to in vitro BVDV 1 
antigen. 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 9. Expression of CD25 on y6 T lymphocytes in response to in vitro BVDV 1 antigen, 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
* Superscript notation indicates significant treatment differences of P<O.OS compared to 
nonvaccinate group. 
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Figure 10. Expression of CD25 on CD4'*^T lymphocytes in response to in vitro BHV-1 
antigen. 
^Nlumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 11. Expression of CD25 on CDS"  ^T lymphocytes in response to in vitro BHV-1 
antigen. 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 12. Expression of CD25 on yS T lymphocytes in response to w v/7ro BHV-1 antigen, 
dumber of animals in each treatment group responding with expression 
index > 5. 
 ^Number of blood samples from each treatment group responding with expression 
index > 5. Data are pooled from 4 post vaccination sampling periods for each animal. 
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Figure 13. Changes in leukocyte count following challenge with virulent BVDV 2 at 5 
months after vaccination. 
* Superscript notation indicates significant treatment differences of P<O.OS compared to 
nonvaccinate group. 
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Figure 14. Changes in neutrophil count following challenge with virulent BVDV 2 at 5 
months after vaccination. 
^Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure IS. Changes in lymphocyte count following challenge with virulent BVDV 2 at 5 
months after vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 16. Changes in monocyte count following challenge with virulent BVDV 2 at 5 
months after vaccination. 
* Superscript notation indicates significant treatment differences of P<O.OS compared to 
nonvaccinate group. 
108 
4 6 8 
Days post challenge 
10 12 14 
• Bovishiefcl -a-CEttlenBSter -^nan-\aocinBles -^Hanun -x-! 
Figure 17. Changes in hemoglobin concentration following challenge with virulent BVDV 2 
at 5 months after vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 18. Changes in platelet counts following challenge with virulent BVDV 2 at 5 months 
after vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 19. Changes in eosinophil counts following challenge with virulent BVDV 2 at 5 
months after vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 20. Changes in basophil counts following challenge with virulent BVDV 2 at 5 
months after vaccination. 
Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figure 21. Changes in rectal temperature following challenge with virulent BVDV 2 at 5 
months after vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Figxire 22. Clinical signs following challenge with virulent BVDV 2 at 5 months after 
vaccination. 
* Superscript notation indicates significant treatment differences of P<0.05 compared to 
nonvaccinate group. 
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Table 1. Description of clinical score assignments for challenge with BVDV. 
Depression Score 
Normal 0 bright, alert 
eyes bright 
ears erect 
chew cud 
curious, attentive 
stays with group 
stretches back muscles, hind legs vh^en stands up 
licks nostrils frequently 
Mild 1 ears droop slightly 
rarely stands alone 
licks nostrils occasionally 
tries to stay with group 
difficult to comer or nearly impossible to catch in corral 
Moderate 2 walks slowly 
lethargic 
stands alone for prolonged periods 
sometimes stands with head low 
easy to comer, but would be difficult to catch 
Severe 3 uninterested in environment 
very lethargic, apathetic 
stands with head lowered most of the time 
a "stmggler" 
lies in sternal recumbency frequently 
often recumbent, reluctant to stand but can stand when encouraged 
easy for one person to catch 
Sickness Score 
0 healthy animal 
no clinical signs 
no treatment required 
1 sick animal, animal would be treated 
this is the severity of disease at which the animal should first be 
noticed as sick and treated 
recovery would be expected with ^ propriate ther^y 
2 obviously sick animal, would be treated 
obvious clinical signs 
disease is now serious, animal should have been treated before 
disease progressed to this point 
recovery would not be certain 
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Table 1 (contM) Description of clinical score assignments for challenge with BVDV. 
Sickness Score (cont'd) 
3 very sick animal, disease very serious 
severe clinical signs 
recovery imlikely even with therapy 
Nasal Discharee Score 
Serous 1 
2 
3 
Clear Discharge - confined to nares 
Clear Discharge - outside of nares but confined to muzzle 
Clear Discharge - streaming or dripping from muzzle 
Mucus 2 
4 
6 
Off ^ ^te, thick discharge - confined to nares 
Off white, thick discharge - outside of nares but confined 
to muzzle 
Off white, thick discharge - streaming or dripping from muzzle 
Mucopurulent 3 
6 
9 
Yellow-green, thick discharge - confined to nares 
Yellow-green, thick discharge - outside of nares but confined 
to muzzle 
Yellow-green, thick discharge - streaming or dripping from 
muzzle 
Blood Tinged 3 Any discharge containing a significant amount of blood prior 
to swabbing 
Ocular Discharee Score 
Serous 1 Clear running fluid external to the eye, running down face 
Mucus 2 Significant off white discharge in the eye or running down 
the face 
Mucopurulent 3 Significant yellow-green thick discharge in the eye or running 
down the face 
Oral Lesions Score 
Normal 0 No lesions present 
Mild 3 < 3 lesions, single site, non-coalescing 
Moderate 6 >3 lesions, single site, may be coalescing 
Severe 9 multiple sites, coalescing 
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Table 1 (cont'd). Description of clinical score assignments for challenge with BVDV. 
Rapid Respiration Score 
Normal 0 Normal respiration 
Mild 1 >35 but <50 breaths/minute 
Severe 2 >50 breaths/minute 
Diarrhea Score 
Normal 0 solid to semi'solid stool 
Mild 2 loose, unformed stool 
Moderate 4 watery stool 
Severe 6 bloody or blood-tinged watery stool, discolored 
Couehine Score 
Normal 0 0 or 1-2 independent coughing episodes 
Mild I 3-5 coughing episodes 
Severe 2 > 5 coughing episodes 
Anorexia Score 
Normal 0 shows interest in feed, eats 
Mild 1 shows interest in feed, does not eat 
Moderate 2 no interest, no eating 
Severe 3 no eating, gaunt, dehydrated 
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CHAPTER 6. CELL MEDL\TED IMMUNITY TO BOVINE VIRAL DIARRHEA VIRUS 
IN CALVES PROTECTED BY MATERNAL ANTIBODY 
A paper to be submitted to Veterinary Microbiology 
J.M. Jones-Endsley, J.R. Ridpath, J.F. Neill, and J. A. Roth 
Abstract 
This study examined antigen specific CIM"*", CD8*, and yd T cell responses and antibody 
responses to in vitro bovine viral diarrhea virus (B VDV) in calves challenged with BVDV in 
the presence of high titered circulating maternal antibody to the virus. Calves (n=12) fed 
colostrum with a high titer against bovine viral diarrhea virus (BVDV) for 48 hrs postpartum 
developed high serum antibody (ab) levels due to uptake of ab fix}m colostrum. Six of the 
colostrum fed calves were exposed to virulent type 2 BVDV at 1-4 weeks of age when senmi 
ab levels were high. These calves did not become clinically ill or have an increase in serum 
ab levels. Calves (n=6) fed milk replacer after birth did not have antibodies against BVDV. 
Three of the milk replacer fed calves were exposed to virulent type 2 BVDV at 1 -4 weeks of 
age, became moribund and were euthanized due to severe BVDV infection. Serum ab titers 
of calves exposed to BVDV following colostrum ingestion declined at a similar rate to 
colostnmi fed calves that were not exposed to virus. BVDV specific CIM"*", CD8"^, or y5 T 
lymphocytes were determined approximately monthly by two-color flow cytometry, using 
CD25 as an activation marker. All surviving calves were challenged with the same virulent 
type 2 BVDV at 7-9 months of age when serum ab titers had declined to undetectable levels. 
Calves exposed to BVDV following colostrum ingestion demonstrated greater activation of 
CD4'^ , CD8" ,^ and y8 T lymphocytes after exposure to in vitro BVDV, and were protected 
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from virulent BVDV challenge, compared to nonexposed animals. These data indicate that 
calves exposed to BVDV while maternal antibody levels are high can develop antigen 
specific CD4 ,^ CD8" ,^ and y6 T lymphocytes in the absence of an active antibody response. 
The calves with T lymphocytes specific for BVDV are also protected from virulent BVDV 
type 2 challenge after maternal antibody becomes undetectable. 
Introduction 
Bovine viral diarrhea virus is a pestivirus responsible for major economic losses to the 
cattle industry due to respiratory, enteric and reproductive disease'. The disease 
manifestation varies with biotype and genotype of the BVDV virus. BVDV isolates are 
designated as either cytopathic or noncytopathic based on the ability to cause cytolysis in cell 
culture'. BVDV can cross the placenta leading to abortion, mummification, or congenital 
defects, and infection with the noncytopathic strains may lead to persistently infected 
animals''. Persistently infected animals are the most common source of disease transmission 
within a herd and represent a serious obstacle to controlling the diseased Superinfection of a 
persistently infected animal with a homologous cytopathic strian may cause a fatal mucosal 
disease"*'^. 
Two genotypes of BVDV have also been designated based on genomic differences in the 
5' untranslated region and differences in the monoclonal antibody binding pattem '^^ . Disease 
caused by type 1 infection in immunocompetent animals is usually mild and transient, while 
disease caused by type 2 can be severe and fi^ equently fatal'*"'. Young calves are protected 
from clinical signs due to either genotype by passively acquired antibody derived from 
colostrum"''^. Maternally derived antibody to BVDV has a half life of approximately 3 
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weeks and is usually catabolized by proximately 6 months of age'^ "'®. High titers of 
maternal antibody are capable of preventing the induction of an active antibody response to 
vaccination in calves'^ . This has lead to the conclusion that it is necessary to wait until 
maternal antibody has waned to effectively induce protective immunity 
Stimulating an immime response to BVDV that is not blocked by matf^al antibody 
could generate a protective memory response to this virus at a much earlier age. Cell 
mediated immime responses to some pathogens of domestic animals can occur in the 
presence of maternal antibody and in the absence of a detectable humoral response'^ ''^ . 
Protective immune responses that are mediated by T lymphocytes may be overlooked due to 
the inability to identiiy them by serology. The objective of the trial reported here and in a 
companion manuscript^  ^was to determine if calves with a high level of maternal antibody to 
B VDV could develop CD4'^ , CDS'*", or y8 T lymphocyte responses to BVDV in the absence 
of a humoral immune response and be protected from challenge by virulent virus. 
Materials and Methods 
Animals 
Eighteen Holstein calves were used to determine if bovine viral diarrhea virus (BVDV) 
specific T lymphocytes are generated ^ ^en calves with circulating maternal antibody are 
challenged with BVDV. The calves were obtained from 2 Iowa dairy farms with no evidence 
of active BVDV infection. All calves were removed from their mothers immediately after 
birth and taken to the USDA Agriculture Research Services National Animal Disease Center 
in Ames, LA within 2 hours of birth. Blood and skin samples were taken from the calves 
prior to colostrum ingestion to determine that the calves were negative for BVDV virus and 
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antibody. The serum samples were tested for presence of antibodies to type 1 type 2 
BVDV. Bloodandskinsamples were tested for presence of BVDV. Bufiy coat samples 
were frozen and thawed, and lysates were passaged twice on bovine turbinate cells (BT). 
The BT cells were subsequently stained with polyclonal serum from a steer hyperimmimized 
with BVDV 1, BVDV 2, and Border disease virus (BDV). Skin samples were sn£q> frozen in 
isopentane and immunohistochemistry was performed using an antibody against the E2 
protein of BVDV as previously described '^. Serum neutralizing antibody titers were also 
determined monthly as previously described .^ All calves received ennofloxacin (Batril 100, 
Bayer Corporation, Shawnee Mission, KS) subcutaneously for 5 days following birth and 
were given a supplemental injection of vitamins A, D, E, & K. 
Milk Source 
Pooled colostrum from cows immimized against BVDV during pregnancy, or milk 
replacer was fed to all calves within 48 hours of birth as described in the companion 
manuscript^ ". The colostrum fed calves received three feedings of colostrum and one feeding 
of first milk (second milking of postpartum cows, not as nutrient and immunoglobulin dense 
as colostrum) before 48 hours of life. The calves fed milk replacer (Arbie Feeds, 
Marshalltown, lA) also received 4 feedings prior to 48 hours of life. All four feedings before 
48 hours were administered with a stomach tube in 2800 ml aliquots. After 48 hours of life 
all calves were fed milk replacer. The colostrum and second milk were obtained from 9 
Jersey cows that had been vaccinated at 8 and 4 weeks prior to parturition. The vaccine used 
to immunize these cows contained an experimental type 1 and type 2 BVDV antigen 
(provided by Fort Dodge Animal Health, Fort Dodge, LA). The colostrum and first milk were 
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frozen at —20 °C immediately after collection. All colostrum and first milk samples were 
later thawed, pooled, and refix>zen in 2800 ml aliquots at -20 ®C until use. The titer of 
neutralizing antibody against type 1 and type 2 BVDV in the colostrum and first milk was 
determined as previously described .^ The serum neutralising antibody titer of the pooled 
colostrum to genotype 1 BVDV ( strain NY-1) was 1/128,000 and titer to genotype 2 (strain 
1373) was 1/4,096,000. The corresponding titers in the first milk were 1/8,192 against 
BVDV 1, and 1/64,000 against BVDV 2. 
Viruses 
Viral stocks of BVDV 2 (strain 1373), BVDV lb (strain NY-1), BVDV 2 (strain 890), 
and BVDV 1 (strain TGAN) were propagated as described previously®. BVDV 1 (strain 
970) virus was grown in bovine turbinate (BT) cells in McCoys 5A medium supplemented 
with 10% fetal bovine serum that was free of BVDV virus and antibodies. Flasks of BT cells 
were seeded for 24 hours and infected with 10® TCIDso of BVDV. Virus was grown for 48 
hours and frozen at — 80**C. Culture flasks were then thawed and cell culture media 
centriiuged at 2,000 x g to remove cellular debris. Viral titers were determined as described 
previously^ .^ The virulent challenge virus, BVDV 2 (strain 1373), was obtained from Dr. 
Susy Carman (Animal Health Laboratory, University of Guelph, ON NIH 6R8, Canada). It 
was isolated from an outbreak of severe acute BVDV in Ontario, Canada^ .^ All viruses were 
noncytopathic as determined by activity in cell culture  ^and the production of the NS3 
polypeptide^®. 
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Challenge 
Calves receiving colostrum or milk replacer were assigned to 1 of 4 treatment groups. 
Group 1 consisted of 6 calves that received the colostrum with a high titer of antibody against 
BVDV, but were not challenged with BVDV. Group 2 consisted of 6 calves that also 
received colostrum with a high titer of antibody against BVDV, and were challenged with 
BVDV 2-1373 at 6-20 days of age. Group 3 consisted of three calves that were fed milk 
replacer after birth and were not challenged with BVDV. Group 4 consisted of 3 calves that 
received milk replacer after birth and were challenged with BVDV2-1373 at 6-20 days of 
age. It was difScult to acquire enough animals of similar age to challenge all animals on the 
same date. Twelve animals were acquired in February and groups of three were randomly 
assigned to one of the four treatment groups (block 1). Another group of six animals was 
acquired in April and three animals were randomly assigned to either group 1 or group 2 
treatments (block 2). Animals in group 2 and 4 were inoculated intranasally with 5 ml (2.5 
ml in each nostril) of fteeze/thaw lysate from cultured bovine cells infected with BVDV2-
1373. The titer of the inoculum was 10  ^multiplicity of infection/ml. The inoculated animals 
were housed separately from the non-inoculated animals for the remainder of the trial. The 
animal handlers changed boots and coveralls, and washed hands between housing facilities. 
The animals that were inoculated with BVDV were always cared for after the non-inoculated 
animals. Following inoculation, all animals were sampled ^ proximately monthly for 
antibodies to BVDV and T lymphocytes specific for BVDV. Antibodies of maternal origin 
were monitored until they were no longer detectable in the serum of calves in all treatment 
groups. At this time, all animals were challenged with BVDV 2 (strain 1373) as described 
above to determine if they had protective immunity. 
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Measurement of T cell Activation 
Antigen specific T cell subset activation was detected using a modification of a 
previously described procedure^^. Animals in all treatment groups were sampled for in vitro 
T cell responsiveness approximately monthly from 0 to 32 weeks following birth. Peripheral 
blood mononuclear cells (PBMC) were isolated from 50 ml citrated blood, washed twice in 
Hanks balanced salt solution (HBSS), and resuspended at 4 x 10  ^cells in 200 ^ 1 of RPMI 
media containing 2 mM L-glutamine, penicillin (60 ng/ml), 20 mM HEPES, and 7.5 % fetal 
calf serum. Triplicate wells of PBMCs were cultured alone and with BVDV 2 (strain 890), 
BVDV 2 (strain 1373), BVDV 1 (strain 970), BVDV 1 (strain TGAN), or Concanavalin A 
for 5 days at 39 °C in a 5% CO2 atmosphere. The amount of viral antigen used in the CD25 
expression assay was based on levels >^ch gave an optimal response in animals which had 
been previously vaccinated with modified live BVDV vaccine containing BVDV 1. 
Following the 5 days of culture, cells were washed twice with Hanks balanced salt 
solution (HBSS) and twice with a phosphate buffered saline (PBS) solution containing 0.5% 
bovine serum albumin and 0.1% NaNa (PBS" .^ All wash steps were performed using an 8 
channel plate washer with gravity flow. The washed cells were then stained with murine 
monoclonal antibodies specific for bovine CD4 (CACTI 38A), CDS (CACT80C), and yS 
(GB21 A) T cells and a murine monoclonal antibody specific for CD25 
(CACTI08A)(VMRD, Pullman, WA). The antibodies specific for CD4, CDS, and a matched 
isotype control were an IgGl isotype. Antibodies specific for yS TCR and a matched isotype 
control were an IgG2b isotype. The antibody specific for CD25 was an IgG2a isotype. 
Following a 30 minute incubation at 4® C, cells were washed 4 times with PBS"*  ^and then 
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stained with phycoeiythrin labeled anti-murine IgG2a and fluorescein isothiocyanate labeled 
anti-murine IgG2b (yS and isotype control) or anti-IgGl (CD4, CDS, and isotype 
control)(Caltag, Burlingame, CA). After 30 minutes at 4° C, cells were washed 5 times in 
HBSS without phenol red and fixed in 1% paraformaldehyde. Triplicate wells were pooled 
prior to cotmting. Serum was also tested monthly to determine the level of neutralizing 
antibody titers to BVDV 1 (strain NY-1) and BVDV 2 (strain 1373). 
Data Analysis 
Antigen specific T cell responsiveness to in vitro antigen was determined by analyzing a 
total of 5,000 cells using a flow cytometer (Becton Dickinson FACScan, San Jose, CA). 
Data are reported as a CD25 expression index, which is a ratio of the lymphocyte 
responsiveness from each animal when stimulated with antigen versus when not stimulated 
with antigen. Expression Index = (% stimulated T cells positive for CD25) * (mean 
fluorescent intensity of stimulated T cells positive for CD25) / (% unstimulated T cells 
positive for CD25) • (mean fluorescent intensity of unstimulated T cells positive for CD25). 
Data are reported as treatment means plus the standard error of the mean. The T cell 
responses to antigen by the second block of animals were not measured at exactly the same 
number of weeks following colostrum ingestion as the first block of animals. For clarity of 
presentation, the expression indices are pooled by 10 week intervals following the first 
challenge with BVDV. 
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Results 
Serum neutralizing antibody titers and response to challenge 
Calves that were fed milk replacer after birth did not have detectable serum neutralizing 
antibodies to either genotype of BVDV^°. At one week of age, colostrum and first milk fed 
calves had geometric mean titers of 2,211 to BVDV 1 and 11,456 to BVDV 2. The 
antibodies to BVDV 1 and BVDV 2 from colostrum fed calves declined at similar rates for 
the challenged calves compared to the unchallenged calves (Figure 1). The antibody titer 
dropped to undetectable levels by 9 months of age for ail colostrum fed calves in the first 
treatment block and by 7 months of age for all colostrum fed calves in the second treatment 
block. The group of colostrum fed calves that was challenged with virulent BVDV 2 (strain 
1373) a few weeks after colostrum ingestion (group 2) did not show signs of acute disease. 
The group of milk replacer fed calves that was challenged with BVDV 2 (strain 1373) at this 
same time point (group 4) became moribund and were euthanized The level of serum 
neutralizing antibody to either genotype of BVDV did not increase in the colostrum fed 
calves following viral challenge (Figure 1). One calf from group 2 died at 1 month of age 
from an illness unrelated to BVDV infection. 
Antigen specific upregulation of CD25 on T cell subsets after first exposure to BVDV 
Calves from group 2 were challenged with virulent BVDV at 6-20 days following 
ingestion of colostrum. The calves in all groups were sampled for T lymphocyte subset 
responsiveness to four strains of BVDV in vitro, approximately monthly, until maternal 
antibodies were no longer detectable (between 7-9 months of age). Antigen specific CD4  ^
CD8"  ^and y5 T cell activation in response to both genotype 1 and genotype 2 BVDV strains 
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in vitro, as indicated by CD25 expression, was detected in calves challenged with BVDV 
while they had high titers of maternal antibody. Variation of the response of the three 
subsets of lymphocytes to the four strains of BVDV was observed (Figures 2-5). The T 
lymphocyte responses of the group 3 calves to BVDV were not significantly (P<0.05) 
different from the T lymphocyte responses of the group 1 calves to BVDV (data not shown). 
Calves from all remaining treatment groups were challenged with BVDV 2 strain 1373 
when maternal antibodies were no longer detectable in peripheral blood. As described^", the 
calves in group 2 that had previously been exposed to BVDV when maternal antibody levels 
were high were protected from challenge compared to the animals from groups 1 and 4 that 
had not been previously exposed. 
Discussion 
Calves challenged with virulent BVDV 2 were protected from clinical signs by maternal 
antibody obtained through ingestion of colostrum. This is in agreement with previous reports 
indicating protection from genotype 1 and genotype 2 BVDV infection by high titer maternal 
antibodies' This is the first report to demonstrate that calves challenged with BVDV 
while maternal antibody levels are high can develop BVDV specific T lymphocyte subset 
responses to in vitro antigen. This T lymphocyte response occurred in the absence of a 
detectable humoral immune response to BVDV in the challenged calves. In the current trial, 
individual T cell subsets from colostrum fed, BVDV challenged calves were all activated to 
some degree in response to the homologous BVDV genotype. This is in agreement with a 
previous report of 004* ,^ CDS*  ^and yS T cells activated by in vitro antigen following 
vaccination with modified live BVDV vaccine '^. Detection of CD25 expression does 
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indicate activation by specific antigen, but does not give any information on the fimction of 
responding T cells '^^ '. The CD4"  ^and CDS"*  ^T cells activated by BVDV are expected to 
provide cytokines and induce cytotoxic effects on infected cells, respectively. In the current 
trial, detection of significant CD4  ^and CDS"  ^responses to a genotype of BVDV heterologous 
to the challenge strain may indicate that cross protective epitopes are presented to T 
lymphocytes following BVDV exposure. Vaccination of cattle with modified live vaccine 
containing BVDV 1 protects cattle from BVDV 2 challenge^ .^ A tendency toward greater 
activation of specific CD4\ CDS"*", or y5 T cells to in vitro BVDV 2 was observed following 
vaccination of cattle with a modified live vaccine containing BVDV 1 '^^ ®. It is interesting 
that in the current trial, CD4* responses were greatest against the homologous genotype, 
while strong CDS"  ^responses were observed against the homologous and the heterologous 
genotype. 
In the current trial, y8 T cells were activated by all strains of BVDV in vitro. This result 
may reflect the less specific nature of the y5 T cell population in response to antigen '^. The 
precise role of y5 T cells in cattle and other species is not well defined, making it difficult to 
explain the biological significance of antigen specific y5 T cells following vaccination. 
Gamma delta T cells have been shown to act as antigen presenting cells and cytotoxic T 
lymphocytes in cattle and as helper T cells in mice^^ .^ The T cell subset responses to the 
BVDV 2 890 strain were more consistent than to the homologous challenge BVDV 2 1373 
strain. The challenge strain is highly virulent and may have a suppressive effect on antigen 
specific T cells in vitro compared to strain 890. 
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The development of T cell memory to pathogens in the absence of an antibody response 
has been described for other viruses in animals with circulating matemal antibody. Calves 
challenged with BHV-1 while matemal antibody levels were high had T lymphocytes that 
proliferated and secreted IFNy in response to in vitro BHV-1 antigen in the absence of a 
measurable antibody response"''*. Antigen specific T cell proliferation or cytokine secretion 
in the absence of an antibody response has also been described in cattle vaccinated against 
BRSV'^ , neonatal mice vaccinated against measles ,^ pigs vaccinated against psuedorabies^ ,^ 
and human neonates exposed to various enteroviruses^ .^ Cell mediated immune responses do 
not always occur in the face of matemal antibody, however. Matemal antibody inhibits the 
proliferative response of T cells to antigen in mice exposed to malaria^  ^and dogs exposed to 
rabies or dogs exposed to Sendai virus '^. In a direct comparison, matemal antibody in mice 
was shown to inhibit the generation of a cytotoxic T cell (CTL) response to respiratory 
syncytial virus (RS V), but not influenza virus '^. The ability of a young animal to generate a 
memory T cell response to antigen in the face of matemal antibody may vary with individual 
pathogens. 
The route of inoculation may also affect the ability of an individual to develop a memory 
T cell response to a pathogen. Psuedorabies inoculation of pigs with matemal antibody 
resulted in a strong T cell proliferative response to m vitro PRV when an intranasal 
inoculation protocol was used^ .^ The T cell response was absent when an intramuscular 
(i.m.) inoculation protocol was followed in the same smdy. Calves with high passive 
antibody to BHV-1 demonstrated a lymphoproliferative response to antigen following i.m. 
vaccination and had a significant IFNy secretion response following intranasal 
inoculation'^ *'^ . There appears to be no difference between i.m. and intraperitoneal (i.p.) 
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incoiuation, as mice inoculated with measles virus either i.m. or i.p. in the study had T 
cells that proliferated and secreted IFNy in response to in vitro measles antigen .^ The 
current study examined T cell responses following an intranasal inociilation with virulent 
BVDV. An intranasal inoculation best simulates the natural route of infection, however, 
BVDV vaccines are administered i.m. or subcutaneously (s.c.). It would be very interesting 
to compare intranasal inoculation with i.m., or s.c. of BVDV in calves with maternal 
antibody. 
The results of the cuirent trial demonstrate that calves can be seronegative for BVDV 
and still have immime memory due to an exposure to the virus during the presence of 
maternal antibody. This conflicts with the current practice of identifying BVDV naive and 
susceptible animals based on the absence of acquired antibody. Currently, a calf is 
considered to be immunologically naive to BVDV if virus cannot be isolated and the animal 
is seronegative after matemal antibody has waned. The existence of seronegative calves that 
have T cell memory to BVDV could significantly impact interpretations of immune 
responses of calves to BVDV infection or vaccination. 
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Figure I. Geometric mean serum neutralizing antibody titer (log) to genotype 1 BVDV 
(strain NY-1) (A) and to the challenge strain of genotype 2 BVDV (strain 1373) (B) 0-8 
months after challenge. Group 1 calves were fed colostrum and not challenged with 
BVDV. Group 2 calves were fed colostrum and challenged with BVDV 2 (strain 1373) at 
6-20 of age. The milk replacer fed calves (group 2) did not have detectable antibody titers 
to BVDV. 
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Figure 2. CD25 expression index (mean + SEM) for T cell subsets stimulated in vitro with 
BVDV 2 (strain 1373) from; calves fed colostrum and not challei^ ed with BVDV (group 1), 
calves fed milk replacer and not challenged with BVDV (group 3) and calves fed colostrum 
and challenged with BVDV 2 (strain 1373) at 6 to 20 days of age (group 2). Data for each 
group from weeks 0-10 (n=33); 11-20 (n=37); and 21-32 (n=31) after challenge were pooled. 
*^<0.05, ••/*<0.01; level of statistical significance between vaccinate and non-vaccinate 
values (mean + SEM). 
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Figure 3. CD25 expression index (mean + SEM) for T cell subsets stimulated in vitro with 
BVDV 2 (strain 890) from: calves fed colostrum and not challenged with BVDV (group 1), 
calves fed milk replacer and not challenged with BVDV (group 3) and calves fed colostrum 
and challenged with BVDV 2 (strain 1373) at 6 to 20 days of age (groiq> 2). Data for each 
group from weeks 0-10 (n=33); 11-20 (n=37); and 21-32 (n=31) after challenge were pooled. 
•P<0.05, ••P<0.01; level of statistical significance between vaccinate and non-vaccinate 
values (mean + SEM). 
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Figure 4. CD25 Expression Index (mean + SEM) for T cell subsets stimulated in vitro with 
BVDV 1 (strain 970) from: calves fed colostrum and not challenged with BVDV (group 1), 
calves fed m ilk replacer and not challenged with BVDV (groiq> 3) and calves fed colostrum 
and challenged wi& BVDV 2 (strain 1373) at 6 to 20 days of age (group 2). Data for each 
group from weeks 0-10 (n=33); 11-20 (n=37); and 21-32 (n=31) after challenge were pooled. 
*P<0.05, ••/*<0.01; level of statistical significance between vaccinate and non-vaccinate 
values (mean + SEM). 
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Figure 5. CD25 expression index (mean + SEM) for T cell subsets stimulated in vitro with 
BVDV 1 (strain TGAN) from: calves fed colostrum and not challenged with BVDV (group 1), 
calves fed milk replacer and not challenged with BVDV (group 3) and calves fed colostrum 
and challenged with BVDV 2 (strain 1373) at 6 to 20 days of age (group 2). Data for each 
group from weeks 0-10 (n=33); 11-20 (n=37); and 21-32 (n=31) after challenge were pooled. 
*P<0.05, **P<0.01; level of statistical significance between vaccinate and non-vaccinate 
values (mean + SEM). 
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CHAPTER 7: GENERAL CONCLUSIONS 
General discussion 
The research presented in this dissertation is an important step towards understanding 
the role of different T lymphocyte subsets in response to BVDV and BHV-1. CD4'*", CDS" ,^ 
and yS T lymphocyte subsets that were specific for BVDV genotype 1, BVDV genotype 2, 
and BHV-1 were detected in cattle following vaccination with modified live vaccines. 
Calves with maternal antibodies at levels that blocked a humoral immune response to BVDV 
2 developed CD4" ,^ CDS'*", and yS T lymphocytes specific to BVDV 2 following challenge. 
The calves with T l3anphocytes specific for BVDV due to challenge vsiien maternal 
antibodies were high were also protected from a second challenge with BVDV after maternal 
antibodies had waned. The protection of animals against BVDV challenge is correlated with 
the specific T cell responses, but this relationship can only be inferred from the current trials. 
The generation of immune responses that protect cattle against the broad range of 
genetically diverse strains of BVDV is very important for developing protective vaccines. 
The data presented here indicate that the T cell subset response (especially CD4"^ to BVDV 
that is generated by vaccination or experimental challenge may be greater against the 
homologous genotype than the heterologous genotype. Protective immunity to heterologous 
BVDV may be generated in vivo, but is not as detectable in an in vitro assay as immunity to 
the homologous strain. 
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Recommendations for future research 
004" ,^ CDS"*", and y8 T lymphocytes that are specific for BVDV and BHV-1 have been 
detected in cattle exposed to these viruses. The next important step will be characterization of 
the activities of T lymphocyte subsets responding to BVDV and BHV-1. The CD8  ^
and y5 T lymphocytes responding to BVDV and BHV-1 antigens probably have different 
roles. Detection of cytokine secretion, cytolytic activity against BVDV or BHV-1 infected 
cells, or antigen presentation by these cells would help characterize their roles in protective 
immunity. It is very likely that the responding T lymphocyte subsets are providing help for 
one another to proliferate and/or to become activated. It is also possible that one or more T 
cell subsets is being activated nonspecifically by cytokines from a T cell subset that is 
specifically activated by antigen. To separate these effects, it will be necessary to study the 
activity of T lymphocytes in response to BVDV and BHV-1 when one or more other subsets 
have been removed. Magnetic bead separation could be used to deplete one or more cell 
populations prior to incubating the remaining T lymphocyte subset(s) with antigen. Since 
peripheral blood mononuclear cells are used in the assay, it will also be important to remove 
B cells and monocytes to fiirther characterize their roles in activating the T lymphocytes. 
Monocytes would be expected to present antigen to CD4'^  helper T cells, especially when 
infected with BVDV. There is the possibility, however, that another cell type is serving the 
antigen presentation fimction. 
Determining the role of gamma delta T lymphoyctes in response to BVDV will also 
require depletion of the other T lymphocyte subsets. Although depleting the yS T 
lymphocyte population is not difficult, defining the role of this T cell subset in the absence of 
the ap T lymphocytes could be difficult The costimulatory signals and growth factors 
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necessary for yS T lymphocyte activation are not as well defined. Interleukin 2 can be added 
to the CD4* and CDS"*  ^T lymphocytes to simulate the effects of helper cytokines. This 
growth cytokine may not provide the right activation signal for yS T lymphocytes. 
Experimentation with cytokines known to activate mouse and human y5 T lymphocytes may 
answer the question of >^ch cytokines are needed to activate bovine y5 T lymphocytes. If 
y5 T lymphocytes can be activated specifically by BVDV or BHV-1, it will be important to 
characterize how antigen is being presented and recognized. 
Once the activities of T cell subset(s) that are specifically activated by BVDV and BHV-
1 are characterized, the nature of the antigen that activates these cells can be explored. A 
very important focus for vaccine research will be the identification of immunodominant 
epitopes of BVDV proteins that generate cross-fHOtective T lymphocyte responses to both 
genotypes of the virus. The generation of recombinant BVDV proteins that can be presented 
to T lymphocytes in vitro will greatly speed up the process of determining important 
epitopes. In addition, the use of recombinant proteins will help overcome the potential for 
immune deviation in the in vitro assays due to BVDV infection of the cells in the assay. 
To determine the precise role of T cell subsets in protective immunity, the presence of 
antigen specific T lymphocytes must be directly correlated with challenge protection. In an 
inbred population of animals (e.g. mice), challenge protection and specific T cell responses 
could be correlated by transferring T cells from immune animals to naive animals prior to 
challenge. In out-bred populations, such as cattle, this kind of experiment would be 
extremely costly and difficult. The development of a small animal model for BVDV or 
BHV-1 infection may help to define the roles of T cell subsets in protective immunity by 
allowing adoptive transfer experiments. 
141 
ACKNOWLEDGEMENTS 
No person is solely responsible for her own success. I would like to take a brief moment 
to thank those who have helped me accomplish this major academic milestone. My family 
and friends have been constant supporters of my academic pursuits during the decade that 
I've been in college and always let me know how proud they are of me. I would like to thank 
the "Roth gang" for all their help and friendliness during the past three years. It is great to 
work in an enviroimient with so many talented and interesting people. I am also appreciative 
of how the members of my graduate committee have been involved in many aspects of my 
graduate education, showing genuine interest in my progress. Eh-. Roth especially deserves 
thanks for his thoughtfril guidance and for providing many opportunities for me to present 
our research and to network in the scientific community. A million thanks go to my husband 
and best friend Mark, >k^o has more faith in my ^ ilities than anyone. Our beautiful daughter 
Jessi was not especially helpful in finishing this dissertation, but she has brought more joy 
and fulfillment to my life than I ever thought possible. 
